Immunoglobulin-binding protein and affinity carrier using same
Mutant immunoglobulin-binding proteins with specific mutations address the alkali resistance issue in Protein A-based affinity purification, ensuring stable antibody binding and carrier performance through repeated alkaline washes.
Patent Information
- Application Number
- JP2023109911
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-04-08
- Filing Date
- 2023-07-04
- Publication Date
- 2024-12-05
- Estimated Expiration
- 2039-08-23
AI Technical Summary
Existing affinity purification columns using natural immunoglobulin-binding domains of Protein A suffer from significant decreases in antibody binding properties due to low alkali resistance, leading to reduced effectiveness with repeated use.
Development of immunoglobulin-binding proteins with mutant polypeptide chains containing specific mutations at key positions, such as substitutions or deletions at positions 3, 6, 11, 24, 25, 39, 46, 49, 58, and 23, enhancing alkali resistance and maintaining immunoglobulin-binding activity even after repeated washings with alkaline solutions.
The mutant immunoglobulin-binding proteins maintain immunoglobulin-binding activity and improve alkali resistance, allowing for repeated use of affinity carriers without significant performance degradation.
Smart Images

Figure 0007595117000001 
Figure 0007595117000002 
Figure 0007595117000003
Abstract
Description
[Technical field]
[0001] The present invention relates to an immunoglobulin-binding protein, an affinity carrier using the same, and a method for isolating an antibody using the affinity carrier. [Background technology]
[0002] In recent years, antibodies have been widely used as research reagents, antibody medicines, etc. Antibodies for these reagents and medicines are generally produced through purification by affinity chromatography. Affinity purification of antibodies uses a column on which a ligand, a substance that specifically binds to immunoglobulins, is immobilized, and the ligand generally used is an immunoglobulin-binding protein such as protein A.
[0003] Protein A is a cell wall protein derived from the gram-positive bacterium Staphylococcus aureus. Protein A has five immunoglobulin-binding domains, called E, D, A, B, and C domains, and each domain can bind to an immunoglobulin independently. In addition to the native immunoglobulin-binding domains of Protein A, engineered immunoglobulin-binding domains are also used as ligands for affinity purification.
[0004] A column for affinity purification of an antibody is usually washed with an alkaline solution and used repeatedly. However, since the native immunoglobulin-binding domain of Protein A has low alkaline resistance, the antibody binding ability of an affinity purification column immobilized with the native domain is significantly reduced during repeated use. Therefore, modified Protein A domains with improved alkaline resistance have been developed. For example, it is widely known that the chemical stability of the immunoglobulin-binding domain of Protein A is improved by substituting Gly at position 29 of the amino acid sequence with Ala (Non-Patent Document 1). Patent Document 1 discloses a method for improving the alkaline resistance of the immunoglobulin-binding domain by substituting Asn in the amino acid sequence of the immunoglobulin-binding domain with an amino acid other than Gln and Cys or deleting the domain. Furthermore, Patent Document 2 discloses a method for improving the alkaline resistance of the C, B, or Z domain of Protein A by deleting three or more consecutive amino acids starting from position 1 or 2 from the N-terminus of the domain. [Prior art documents] [Patent documents]
[0005] [Patent Document 1] International Publication No. 2000 / 023580 [Patent Document 2] International Publication No. 2013 / 109302 [Non-patent literature]
[0006] [Non-Patent Document 1] Journal of Chromatography B,2007,848(1):40-47 Summary of the Invention [Problem to be solved by the invention]
[0007] There is a demand for an affinity carrier with improved alkaline resistance. The present invention provides an immunoglobulin-binding protein containing a mutant polypeptide chain with improved alkaline resistance derived from an immunoglobulin-binding domain, and an affinity carrier using the same. The present invention also provides a method for isolating an antibody using the affinity carrier. [Means for solving the problem]
[0008] The present invention provides the following: [1] An immunoglobulin-binding protein comprising a polypeptide chain consisting of an amino acid sequence having at least 85% identity with any one of the amino acid sequences of SEQ ID NOs: 1 to 6 and 57 to 62, and having at least one mutation selected from the group consisting of the following (a) to (f): (a) substitution or deletion of an amino acid residue at at least one position selected from the group consisting of positions corresponding to positions 3, 6, and 11 of the amino acid sequence of SEQ ID NO:3 with another amino acid residue, or insertion of another amino acid residue before or after said position; (b) substitution or deletion of an amino acid residue at at least one position selected from the group consisting of positions corresponding to positions 24 and 25 of the amino acid sequence of SEQ ID NO:3 with another amino acid residue, or insertion of another amino acid residue at a position before or after said position; (c) a substitution or deletion of the amino acid residue at a position corresponding to position 39 of the amino acid sequence of SEQ ID NO:3 with another amino acid residue, or an insertion of another amino acid residue before or after said position; (d) a substitution or deletion of the amino acid residue at a position corresponding to position 46 of the amino acid sequence of SEQ ID NO:3 with another amino acid residue, or an insertion of another amino acid residue before or after said position; (e) substitution or deletion of an amino acid residue at at least one position selected from the group consisting of positions corresponding to positions 4, 49, and 58 of the amino acid sequence of SEQ ID NO:3 with another amino acid residue, or insertion of another amino acid residue before or after said position; and (f) Substitution or deletion of the amino acid residue at the position corresponding to position 23 of the amino acid sequence of SEQ ID NO:3 with another amino acid residue, or insertion of another amino acid residue before or after said position. [2] The immunoglobulin-binding protein according to [1], wherein the polypeptide chain is a polypeptide chain consisting of an amino acid sequence having at least 85% identity with the amino acid sequence of SEQ ID NO: 3 and having at least one mutation selected from the group consisting of (a) to (f). [3] At least one mutation selected from the group consisting of (a) to (f) (a 1 ) a substitution of Asn to Gln at the position corresponding to position 3 of the amino acid sequence of SEQ ID NO:3; (a 2 ) a substitution of Asn to Ala at the position corresponding to position 3 of the amino acid sequence of SEQ ID NO:3; (a 3 ) a substitution of Asn to Asp at the position corresponding to position 3 of the amino acid sequence of SEQ ID NO:3; (a 4 ) a substitution of Asn to Gln at the position corresponding to position 6 of the amino acid sequence of SEQ ID NO:3; (a 5 ) a substitution of Asn to Ala at the position corresponding to position 6 of the amino acid sequence of SEQ ID NO:3; (a 6 ) a substitution of Asn to Asp at the position corresponding to position 6 of the amino acid sequence of SEQ ID NO:3; (a 7 ) a substitution of Asn to Gln at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (a 8 ) a substitution of Asn to Ala at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (a 9 ) a substitution of Asn to Arg at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (a 10 ) a substitution of Asn to Asp at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (a 11) a substitution of Asn to Cys at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (a 12 ) a substitution of Asn to Glu at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (a 13 ) a substitution of Asn to His at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (a 14 ) a substitution of Asn to Ile at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (a 15 ) a substitution of Asn to Leu at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (a 16 ) a substitution of Asn to Lys at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (a 17 ) a substitution of Asn to Met at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (a 18 ) a substitution of Asn to Phe at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (a 19 ) a substitution of Asn to Thr at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (a 20 ) a substitution of Asn to Trp at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (a 21 ) a substitution of Asn to Tyr at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (a 22 ) a substitution of Asn to Val at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (b 1 ) a substitution of Glu to Asp at the position corresponding to position 24 of the amino acid sequence of SEQ ID NO:3; (b 2 ) a substitution of Glu to Asp at the position corresponding to position 25 of the amino acid sequence of SEQ ID NO:3; (c 1) a substitution of Ser with Lys at the position corresponding to position 39 of the amino acid sequence of SEQ ID NO:3; (c 2 ) a substitution of Ser to Arg at the position corresponding to position 39 of the amino acid sequence of SEQ ID NO:3; (d 1 ) a substitution of Ala to Asp at the position corresponding to position 46 of the amino acid sequence of SEQ ID NO:3; (d 2 ) a substitution of Ala to Glu at the position corresponding to position 46 of the amino acid sequence of SEQ ID NO:3; (d 3 ) a substitution of Ala to Lys at the position corresponding to position 46 of the amino acid sequence of SEQ ID NO:3; (d 4 ) a substitution of Ala to Arg at the position corresponding to position 46 of the amino acid sequence of SEQ ID NO:3; (e 1 ) deletion of Lys at the position corresponding to position 4 of the amino acid sequence of SEQ ID NO:3; (e 2 ) a substitution of Lys to Arg at the position corresponding to position 49 of the amino acid sequence of SEQ ID NO:3; (e 3 ) deletion of Lys at the position corresponding to position 58 of the amino acid sequence of SEQ ID NO:3; (e 4 ) a substitution of Lys with Arg at the position corresponding to position 58 of the amino acid sequence of SEQ ID NO:3; (f 1 ) a substitution of Thr to Arg at the position corresponding to position 23 of the amino acid sequence of SEQ ID NO:3; (f 2 ) a substitution of Thr to Leu at the position corresponding to position 23 of the amino acid sequence of SEQ ID NO:3; and (f 3 ) a substitution of Thr to Ser at the position corresponding to position 23 of the amino acid sequence of SEQ ID NO:3; The immunoglobulin-binding protein according to [1] or [2], which has at least one mutation selected from the group consisting of: [4] At least one mutation selected from the group consisting of (a) to (f) (a 1) a substitution of Asn to Gln at the position corresponding to position 3 of the amino acid sequence of SEQ ID NO:3; (a 2 ) a substitution of Asn to Ala at the position corresponding to position 3 of the amino acid sequence of SEQ ID NO:3; (a 3 ) a substitution of Asn to Asp at the position corresponding to position 3 of the amino acid sequence of SEQ ID NO:3; (a 4 ) a substitution of Asn to Gln at the position corresponding to position 6 of the amino acid sequence of SEQ ID NO:3; (a 5 ) a substitution of Asn to Ala at the position corresponding to position 6 of the amino acid sequence of SEQ ID NO:3; (a 6 ) a substitution of Asn to Asp at the position corresponding to position 6 of the amino acid sequence of SEQ ID NO:3; (a 7 ) a substitution of Asn to Gln at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (a 8 ) a substitution of Asn to Ala at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (a 9 ) a substitution of Asn to Arg at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (a 10 ) a substitution of Asn to Asp at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (a 11 ) a substitution of Asn to Cys at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (a 12 ) a substitution of Asn to Glu at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (a 13 ) a substitution of Asn to His at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (a 14 ) a substitution of Asn to Ile at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (a 15 ) a substitution of Asn to Leu at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (a 16 ) a substitution of Asn to Lys at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (a 17 ) a substitution of Asn to Met at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (a 18 ) a substitution of Asn to Phe at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (a 19 ) a substitution of Asn to Thr at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (a 20 ) a substitution of Asn to Trp at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (a 21 ) a substitution of Asn to Tyr at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (a 22 ) a substitution of Asn to Val at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (a 23 ) substitutions of Asn with Gln at positions corresponding to positions 3, 6, and 11 of the amino acid sequence of SEQ ID NO:3; (a 24 ) a substitution of Asn to Ala at the position corresponding to position 3 of the amino acid sequence of SEQ ID NO:3, and a substitution of Asn to Gln at the position corresponding to position 11; (a 25 ) a substitution of Asn to Asp at the position corresponding to position 3 of the amino acid sequence of SEQ ID NO:3, and a substitution of Asn to Gln at the position corresponding to position 11; (a 26 ) a substitution of Asn to Asp at the position corresponding to position 6 of the amino acid sequence of SEQ ID NO:3, and a substitution of Asn to Gln at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (a 27 ) a substitution of Asn to Asp at the position corresponding to position 3 of the amino acid sequence of SEQ ID NO:3, a substitution of Asn to Asp at the position corresponding to position 6, and a substitution of Asn to Gln at the position corresponding to position 11; (a 28) a substitution of Asn to Ala at the position corresponding to position 3 of the amino acid sequence of SEQ ID NO:3, a substitution of Asn to Asp at the position corresponding to position 6, and a substitution of Asn to Gln at the position corresponding to position 11; (b 1 ) a substitution of Glu to Asp at the position corresponding to position 24 of the amino acid sequence of SEQ ID NO:3; (b 2 ) a substitution of Glu to Asp at the position corresponding to position 25 of the amino acid sequence of SEQ ID NO:3; (c 1 ) a substitution of Ser with Lys at the position corresponding to position 39 of the amino acid sequence of SEQ ID NO:3; (c 2 ) a substitution of Ser to Arg at the position corresponding to position 39 of the amino acid sequence of SEQ ID NO:3; (d 1 ) a substitution of Ala to Asp at the position corresponding to position 46 of the amino acid sequence of SEQ ID NO:3; (d 2 ) a substitution of Ala to Glu at the position corresponding to position 46 of the amino acid sequence of SEQ ID NO:3; (d 3 ) a substitution of Ala to Lys at the position corresponding to position 46 of the amino acid sequence of SEQ ID NO:3; (d 4 ) a substitution of Ala to Arg at the position corresponding to position 46 of the amino acid sequence of SEQ ID NO:3; (e 1 ) deletion of Lys at the position corresponding to position 4 of the amino acid sequence of SEQ ID NO:3; (e 2 ) a substitution of Lys to Arg at the position corresponding to position 49 of the amino acid sequence of SEQ ID NO:3; (e 3 ) deletion of Lys at the position corresponding to position 58 of the amino acid sequence of SEQ ID NO:3; (e 4 ) a substitution of Lys to Arg at the position corresponding to position 58 of the amino acid sequence of SEQ ID NO:3; (f 1 ) a substitution of Thr to Arg at the position corresponding to position 23 of the amino acid sequence of SEQ ID NO:3; (f2 ) a substitution of Thr to Leu at the position corresponding to position 23 of the amino acid sequence of SEQ ID NO:3; (f 3 ) a substitution of Thr to Ser at the position corresponding to position 23 of the amino acid sequence of SEQ ID NO:3; (g 1 ) (a 7 ) and (f 1 ) combination; (g 2 ) (a 7 ) and (f 2 ) combination; (g 3 ) (a 7 ) and (f 3 ) combination; (g 4 ) (a 7 ) and (e 2 ) combination; (g 5 ) (a 7 ) and (e 4 ) combination; (g 6 ) (a 7 ) and (f 1 ) and (e 2 ) combination; (g 7 ) (a 7 ) and (f 2 ) and (e 2 ) combination; and (g 8 ) (a 7 ) and (f 3 ) and (e 2 ) combination, The immunoglobulin-binding protein according to [3], which is any one of the following: [5] The immunoglobulin-binding protein according to any one of [1] to [4], wherein at least one mutation selected from the group consisting of (a) to (f) comprises substitution or deletion of amino acid residues at positions corresponding to at least two of positions 3, 6, 11, 24, 25, 39, 46, 4, 49, 58, and 23 in the amino acid sequence of SEQ ID NO: 3 with other amino acid residues, or insertion of other amino acid residues before or after said positions. [6] The at least one mutation is 23 )~(a 28 ) or (a 1 )~(a 28 ) and any one of the above (b 1 )~(f 3 The immunoglobulin-binding protein according to [5], in combination with any one or more of the following: [7] The immunoglobulin-binding protein according to any one of [1] to [6], wherein the amino acid sequence has at least 90% identity. [8] The immunoglobulin-binding protein according to any one of [1] to [7], wherein the polypeptide chain further comprises a substitution of the amino acid residue at the position corresponding to position 1 of the amino acid sequence of SEQ ID NO: 3 with Val, and / or a substitution of the amino acid residue at the position corresponding to position 29 of the amino acid sequence of SEQ ID NO: 3 with Ala. [9] The immunoglobulin-binding protein according to any one of [1] to [8], which comprises two or more of the polypeptide chains.
[10] A polynucleotide encoding the immunoglobulin-binding protein according to any one of [1] to [9].
[11] A vector comprising the polynucleotide described in
[10] .
[12] A transformant comprising the vector described in
[11] .
[13] An affinity carrier comprising a solid phase carrier and the immunoglobulin-binding protein according to any one of [1] to [9] bound to the solid phase carrier.
[14] A chromatography column comprising the affinity support of
[13] .
[15] A method for isolating an antibody or a fragment thereof, which uses the affinity support described in
[13] or the chromatography column described in
[14] .
[16] A method for producing an immunoglobulin-binding protein, comprising expressing the immunoglobulin-binding protein according to any one of [1] to [9] in the transformant according to
[12] or in a cell-free protein synthesis system, or chemically synthesizing the immunoglobulin-binding protein.
[17] A method for producing a mutant polypeptide chain, comprising the steps of: A method comprising introducing at least one mutation selected from the group consisting of the following (a) to (f) into a polypeptide chain consisting of an amino acid sequence of any one of SEQ ID NOs: 1 to 6 and 57 to 62, or an amino acid sequence having at least 85% identity thereto, and having immunoglobulin-binding activity: (a) substitution or deletion of an amino acid residue at at least one position selected from the group consisting of positions corresponding to positions 3, 6, and 11 of the amino acid sequence of SEQ ID NO:3 with another amino acid residue, or insertion of another amino acid residue before or after said position; (b) substitution or deletion of an amino acid residue at at least one position selected from the group consisting of positions corresponding to positions 24 and 25 of the amino acid sequence of SEQ ID NO:3 with another amino acid residue, or insertion of another amino acid residue at a position before or after said position; (c) a substitution or deletion of the amino acid residue at a position corresponding to position 39 of the amino acid sequence of SEQ ID NO:3 with another amino acid residue, or an insertion of another amino acid residue before or after said position; (d) a substitution or deletion of the amino acid residue at a position corresponding to position 46 of the amino acid sequence of SEQ ID NO:3 with another amino acid residue, or an insertion of another amino acid residue before or after said position; (e) substitution or deletion of an amino acid residue at at least one position selected from the group consisting of positions corresponding to positions 4, 49, and 58 of the amino acid sequence of SEQ ID NO:3 with another amino acid residue, or insertion of another amino acid residue before or after said position; and (f) Substitution or deletion of the amino acid residue at the position corresponding to position 23 of the amino acid sequence of SEQ ID NO:3 with another amino acid residue, or insertion of another amino acid residue before or after said position.
[18] A method for producing an affinity carrier, comprising immobilizing the immunoglobulin-binding protein according to any one of [1] to [9] above onto a solid phase carrier. Effect of the Invention
[0009] The mutant polypeptide chain of the present invention and the immunoglobulin-binding protein containing the same have immunoglobulin binding and improved alkaline resistance. Therefore, the immunoglobulin-binding protein of the present invention is useful as an affinity ligand. The affinity support of the present invention on which the immunoglobulin-binding protein is immobilized can maintain its immunoglobulin-binding activity even after repeated washing with an alkaline solution (Cleaning-in-place, hereinafter also referred to as CIP). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0010] In this specification, the identity of amino acid sequences or nucleotide sequences can be determined using the algorithm BLAST by Carlin and Arthur (Pro. Natl. Acad. Sci. USA, 1993, 90: 5873-5877). Based on this BLAST algorithm, programs called BLASTN, BLASTX, BLASTP, TBLASTN and TBLASTX have been developed (J. Mol. Biol., 1990, 215: 403-410). When using these programs, the default parameters of each program can be used. Specific methods for these analysis methods are known (see [www.ncbi.nlm.nih.gov]).
[0011] As used herein, "at least 85% identity" with respect to amino acid sequences and nucleotide sequences means 85% or more identity, preferably 90% or more identity, more preferably 95% or more identity, even more preferably 97% or more identity, even more preferably 98% or more identity, and even more preferably 99% or more identity. Also, "at least 90% identity" with respect to amino acid sequences and nucleotide sequences means 90% or more identity, preferably 95% or more identity, even more preferably 97% or more identity, even more preferably 98% or more identity, and even more preferably 99% or more identity.
[0012] In the present specification, the "corresponding position" on the amino acid sequence and the nucleotide sequence can be determined by aligning the target sequence with the reference sequence (e.g., the amino acid sequence of SEQ ID NO: 3) so as to give maximum homology to conserved amino acid residues or nucleotides present in each amino acid sequence or nucleotide sequence. The alignment can be performed using a known algorithm, and the procedure is known to those skilled in the art. For example, the alignment can be performed using the Clustal W multiple alignment program (Thompson, JD et al, 1994, Nucleic Acids Res., 22:4673-4680) with default settings. Clustal W can be used, for example, on the website of the European Bioinformatics Institute (EBI [www.ebi.ac.uk / index.html]) or the DNA Data Bank of Japan (DDBJ [www.ddbj.nig.ac.jp / index.html]) operated by the National Institute of Genetics.
[0013] As used herein, amino acid residues are also referred to by the following abbreviations: alanine (Ala or A), arginine (Arg or R), asparagine (Asn or N), aspartic acid (Asp or D), cysteine (Cys or C), glutamine (Gln or Q), glutamic acid (Glu or E), glycine (Gly or G), histidine (His or H), isoleucine (Ile or I), leucine (Leu or L), lysine (Lys or K), methionine (Met or M), phenylalanine (Phe or F), proline (Pro or P), serine (Ser or S), threonine (Thr or T), tryptophan (Trp or W), tyrosine (Tyr or Y), valine (Val or V), and any amino acid residue (Xaa or X). Furthermore, in this specification, the amino acid sequence of a peptide is written in accordance with conventional practice such that the amino terminus (hereinafter referred to as the N-terminus) is located on the left and the carboxyl terminus (hereinafter referred to as the C-terminus) is located on the right.
[0014] As used herein, the terms "before" and "after" a specific position in an amino acid sequence refer to the positions adjacent to the N-terminus and C-terminus of the specific position, respectively. For example, when an amino acid residue is inserted "before" or "after" a specific position, the inserted amino acid residue is located at the positions adjacent to the N-terminus and C-terminus of the specific position.
[0015] As used herein, the term "immunoglobulin-binding protein" refers to a protein having binding activity to an antibody or a fragment thereof. As used herein, the term "antibody" may include any class of immunoglobulin, such as IgG, IgA, IgD, IgE, IgM, and subclasses thereof, as well as fragments and variants thereof. As used herein, the term "antibody" may also refer to a chimeric antibody such as a humanized antibody, an antibody complex, or another immunoglobulin modification that includes an antigen recognition site. As used herein, the term "antibody fragment" may refer to an antibody fragment that includes an antigen recognition site or an antibody fragment that does not include an antigen recognition site. Examples of antibody fragments that do not include an antigen recognition site include proteins consisting of only the Fc region of an immunoglobulin, Fc fusion proteins, and variants and modifications thereof.
[0016] As used herein, the term "immunoglobulin-binding domain" refers to a functional unit of a polypeptide contained in an immunoglobulin-binding protein, which has immunoglobulin (or antibody or antibody fragment)-binding activity by itself. Preferred examples of the "immunoglobulin-binding domain" include the immunoglobulin-binding domain of protein A and mutants thereof having immunoglobulin-binding activity.
[0017] 1. Immunoglobulin-binding proteins The immunoglobulin-binding protein of the present invention comprises at least one mutant polypeptide chain derived from the immunoglobulin-binding domain of Staphylococcus aureus protein A (hereinafter also referred to as SpA). The mutant polypeptide chain contained in the immunoglobulin-binding protein of the present invention is a polypeptide chain having immunoglobulin-binding activity, and is also referred to as "mutated immunoglobulin-binding domain of the present invention" in the following specification. The mutant immunoglobulin-binding domain of the present invention can be obtained by adding a predetermined mutation to the immunoglobulin-binding domain derived from SpA, which is a parent domain, or a mutant thereof. The mutant immunoglobulin-binding domain of the present invention has immunoglobulin-binding activity and has improved alkali resistance compared to the parent domain. The immunoglobulin-binding protein of the present invention containing the mutant immunoglobulin-binding domain of the present invention can be used as a ligand for an affinity carrier.
[0018] Parent domains of the mutant immunoglobulin-binding domain of the present invention include immunoglobulin-binding domains of SpA, such as domain A, domain B, domain C, domain D, domain E, or domain Z, which is a modified form of domain B, and mutants thereof. Among these, domain B, domain Z, domain C, and mutants thereof are preferred, and domain C and mutants thereof are more preferred.
[0019] The B domain, Z domain, C domain, D domain, A domain, and E domain of SpA, and their mutants, can be used as parent domains of the mutant immunoglobulin-binding domain of the present invention. The B domain of SpA is a polypeptide chain consisting of the amino acid sequence of SEQ ID NO: 1. The mutant of the B domain includes a polypeptide chain consisting of an amino acid sequence having at least 85% identity with the amino acid sequence of SEQ ID NO: 1 and having immunoglobulin-binding activity. The Z domain of SpA is a polypeptide chain consisting of the amino acid sequence of SEQ ID NO: 2. The mutant of the Z domain includes a polypeptide chain consisting of an amino acid sequence having at least 85% identity with the amino acid sequence of SEQ ID NO: 2 and having immunoglobulin-binding activity. The C domain of SpA is a polypeptide chain consisting of the amino acid sequence of SEQ ID NO: 3. The mutant of the C domain includes a polypeptide chain consisting of an amino acid sequence having at least 85% identity with the amino acid sequence of SEQ ID NO: 3 and having immunoglobulin-binding activity. The D domain of SpA is a polypeptide chain consisting of the amino acid sequence of SEQ ID NO: 4. An example of a mutant of the D domain is a polypeptide chain consisting of an amino acid sequence having at least 85% identity with the amino acid sequence of SEQ ID NO: 4 and having immunoglobulin-binding activity. The A domain of SpA is a polypeptide chain consisting of the amino acid sequence of SEQ ID NO: 5. An example of a mutant of the A domain is a polypeptide chain consisting of an amino acid sequence having at least 85% identity with the amino acid sequence of SEQ ID NO: 5 and having immunoglobulin-binding activity. The E domain of SpA is a polypeptide chain consisting of the amino acid sequence of SEQ ID NO: 6. An example of a mutant of the E domain is a polypeptide chain consisting of an amino acid sequence having at least 85% identity with the amino acid sequence of SEQ ID NO: 6 and having immunoglobulin-binding activity.
[0020] Therefore, preferred examples of the parent domain in the present invention include a polypeptide chain consisting of the amino acid sequence of any one of SEQ ID NOs: 1 to 6, and a polypeptide chain consisting of an amino acid sequence having at least 85% identity with any one of the amino acid sequences of SEQ ID NOs: 1 to 6 and having immunoglobulin-binding activity. More preferred examples of the parent domain include a polypeptide chain consisting of the amino acid sequence of any one of SEQ ID NOs: 1 to 3, and a polypeptide chain consisting of an amino acid sequence having at least 85% identity with any one of the amino acid sequences of SEQ ID NOs: 1 to 3 and having immunoglobulin-binding activity. Even more preferred examples of the parent domain include a polypeptide chain consisting of the amino acid sequence of SEQ ID NO: 3, and a polypeptide chain consisting of an amino acid sequence having at least 85% identity with the amino acid sequence of SEQ ID NO: 3 and having immunoglobulin-binding activity.
[0021] From the viewpoint of increasing the expression level of the protein in the transformant (PNAS, 1989, 86:8247-8251, Fig. 2) and facilitating the production of a polynucleotide encoding an immunoglobulin-binding protein in which multiple domains are linked (WO2010 / 110288), the parent domain may contain a substitution of Ala to Val at the position corresponding to position 1 of the amino acid sequence of SEQ ID NO: 3. Furthermore, from the viewpoint of improving the chemical stability and increasing the alkali resistance of the immunoglobulin-binding protein, the parent domain may further contain a substitution of Gly to Ala at the position corresponding to position 29 of the amino acid sequence of SEQ ID NO: 3 (Non-Patent Document 1).
[0022] Immunoglobulin-binding domain mutants have been reported that have a protein structure with higher stability than that of a native immunoglobulin-binding domain, in which the N-terminal region of the native immunoglobulin-binding domain has been deleted (WO2013 / 109302, WO2017 / 194596, etc.). Thus, the parent domain may be an immunoglobulin-binding domain mutant in which at least two amino acid residues (e.g., two, four, six, or seven residues) are deleted from the N-terminus of any of the amino acid sequences of SEQ ID NOs: 1 to 6, so long as the parent domain has immunoglobulin-binding activity. Examples of such parent domains include polypeptide chains consisting of the amino acid sequences of SEQ ID NOs: 57 to 62, which are mutant immunoglobulin-binding domains in which 2 to 7 residues are deleted from the N-terminus of the amino acid sequences of SEQ ID NOs: 1 to 6, respectively.
[0023] Therefore, the amino acid sequence having at least 85% identity to any of the amino acid sequences of SEQ ID NOs: 1 to 6 for the parent domain described above may be any of the amino acid sequences of SEQ ID NOs: 57 to 62, or an amino acid sequence having at least 85% identity thereto. Furthermore, the amino acid sequence having at least 85% identity to any of the amino acid sequences of SEQ ID NOs: 1 to 6 may contain Val at a position corresponding to position 1 of the amino acid sequence of SEQ ID NO: 3 and / or contain Ala at a position corresponding to position 29 of the amino acid sequence of SEQ ID NO: 3.
[0024] The mutant of the immunoglobulin-binding domain of SpA can be prepared by modifying the amino acid sequence of the immunoglobulin-binding domain of SpA by inserting, deleting, substituting or deleting amino acid residues, or by chemically modifying amino acid residues, etc. Methods for inserting, deleting, substituting or deleting amino acid residues include known methods such as site-specific mutation of a polynucleotide encoding the domain.
[0025] The mutant immunoglobulin-binding domain of the present invention has the following (a) to (f) with respect to the above-mentioned parent domain: (a) substitution or deletion of an amino acid residue at at least one position selected from the group consisting of positions corresponding to positions 3, 6 and 11 of the amino acid sequence of SEQ ID NO:3 with another amino acid residue, or insertion of another amino acid residue before or after said position; (b) substitution or deletion of an amino acid residue at at least one position selected from the group consisting of positions corresponding to positions 24 and 25 of the amino acid sequence of SEQ ID NO:3 with another amino acid residue, or insertion of another amino acid residue at a position before or after said position; (c) a substitution or deletion of the amino acid residue at a position corresponding to position 39 of the amino acid sequence of SEQ ID NO:3 with another amino acid residue, or an insertion of another amino acid residue before or after said position; (d) a substitution or deletion of the amino acid residue at a position corresponding to position 46 of the amino acid sequence of SEQ ID NO:3 with another amino acid residue, or an insertion of another amino acid residue before or after said position; (e) substitution or deletion of an amino acid residue at at least one position selected from the group consisting of positions corresponding to positions 4, 49, and 58 of the amino acid sequence of SEQ ID NO:3 with another amino acid residue, or insertion of another amino acid residue before or after said position; and (f) a substitution or deletion of the amino acid residue at the position corresponding to position 23 of the amino acid sequence of SEQ ID NO:3 with another amino acid residue, or an insertion of another amino acid residue before or after said position; It is a polypeptide chain obtained by introducing at least one mutation selected from the group consisting of:
[0026] The mutation (a) is a substitution or deletion of an amino acid residue at at least one position selected from the group consisting of positions corresponding to positions 3, 6, and 11 of the amino acid sequence of SEQ ID NO: 3 with another amino acid residue, or an insertion of another amino acid residue before or after the position. At the positions corresponding to positions 3, 6, and 11, the amino acid residue before substitution is preferably Asn, and the other amino acid residue substituted therewith is preferably an amino acid residue other than Ser, more preferably Ala, Arg, Asp, Cys, Gln, Glu, His, Ile, Leu, Lys, Met, Phe, Thr, Trp, Tyr, or Val, and even more preferably Gln. The mutation (a) may be a single mutation of the amino acid residue at the position corresponding to positions 3, 6, or 11 of the amino acid sequence of SEQ ID NO: 3, or may be a multiple mutation in which two or three of the amino acid residues at the positions corresponding to positions 3, 6, and 11 are mutated. For example, the mutation (a) may be a single substitution of an amino acid residue at a position corresponding to positions 3, 6, or 11 of the amino acid sequence of SEQ ID NO: 3, but may also be a multiple substitution in which two or three of the amino acid residues at positions corresponding to positions 3, 6, and 11 are substituted. Preferably, the mutation (a) is 1 ) a substitution of Asn to Gln at the position corresponding to position 3 of the amino acid sequence of SEQ ID NO:3; 2 ) a substitution of Asn to Ala at the position corresponding to the 3rd position of the amino acid sequence of SEQ ID NO:3; 3 ) a substitution of Asn to Asp at the position corresponding to the 3rd position of the amino acid sequence of SEQ ID NO:3; 4 ) a substitution of Asn to Gln at the position corresponding to position 6 of the amino acid sequence of SEQ ID NO:3; 5 ) a substitution of Asn to Ala at the position corresponding to position 6 of the amino acid sequence of SEQ ID NO:3; 6 ) a substitution of Asn to Asp at the position corresponding to position 6 of the amino acid sequence of SEQ ID NO:3; 7 ) a substitution of Asn to Gln at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; 8) a substitution of Asn to Ala at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; 9 ) a substitution of Asn to Arg at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; 10 ) a substitution of Asn to Asp at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; 11 ) a substitution of Asn to Cys at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; 12 ) a substitution of Asn to Glu at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; 13 ) a substitution of Asn to His at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; 14 ) a substitution of Asn to Ile at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; 15 ) a substitution of Asn to Leu at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; 16 ) a substitution of Asn to Lys at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; 17 ) a substitution of Asn with Met at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; 18 ) a substitution of Asn to Phe at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; 19 ) a substitution of Asn to Thr at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; 20 ) a substitution of Asn with Trp at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; 21 ) a substitution of Asn to Tyr at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; 22 ) a substitution of Asn to Val at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; 23 ) substitution of Asn with Gln at positions corresponding to positions 3, 6, and 11 of the amino acid sequence of SEQ ID NO:3; 24 ) a substitution of Asn to Ala at the position corresponding to position 3 of the amino acid sequence of SEQ ID NO:3, and a substitution of Asn to Gln at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; 25) a substitution of Asn to Asp at the position corresponding to position 3 of the amino acid sequence of SEQ ID NO:3, and a substitution of Asn to Gln at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; 26 ) a substitution of Asn to Asp at the position corresponding to position 6 of the amino acid sequence of SEQ ID NO:3, and a substitution of Asn to Gln at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; 27 ) a substitution of Asn to Asp at the position corresponding to position 3 of the amino acid sequence of SEQ ID NO:3, a substitution of Asn to Asp at the position corresponding to position 6, and a substitution of Asn to Gln at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3, or 28 ) a substitution of Asn to Ala at the position corresponding to position 3 of the amino acid sequence of SEQ ID NO:3, a substitution of Asn to Asp at the position corresponding to position 6, and a substitution of Asn to Gln at the position corresponding to position 11.
[0027] The mutation (b) is a substitution or deletion of an amino acid residue at at least one position selected from the group consisting of positions corresponding to positions 24 and 25 of the amino acid sequence of SEQ ID NO: 3 with another amino acid residue, or an insertion of another amino acid residue at a position before or after the position. At the positions corresponding to positions 24 and 25, the amino acid residue before the substitution is preferably Glu, and the other amino acid residue substituted therewith is preferably Asp. The mutation (b) may be a single mutation of the amino acid residue at the position corresponding to positions 24 or 25 of the amino acid sequence of SEQ ID NO: 3, or a double mutation in which both of the amino acid residues at the positions corresponding to positions 24 and 25 are mutated. For example, the mutation (b) may be a single substitution of the amino acid residue at the position corresponding to positions 24 or 25 of the amino acid sequence of SEQ ID NO: 3, or a double substitution in which both of the amino acid residues at the positions corresponding to positions 24 and 25 are substituted. Preferably, the mutation (b) is 1 ) a substitution of Glu to Asp at the position corresponding to position 24 of the amino acid sequence of SEQ ID NO:3; or 2 ) A substitution of Glu to Asp at the position corresponding to position 25 of the amino acid sequence of SEQ ID NO:3.
[0028] The mutation (c) is a substitution or deletion of the amino acid residue at the position corresponding to position 39 of the amino acid sequence of SEQ ID NO: 3 with another amino acid residue, or an insertion of another amino acid residue before or after the position. At the position corresponding to position 39, the amino acid residue before the substitution is preferably Ser, and the other amino acid residue substituted therewith is preferably Lys or Arg. Preferably, the mutation (c) is 1 ) a substitution of Ser to Lys at the position corresponding to position 39 of the amino acid sequence of SEQ ID NO:3, or 2 ) a substitution of Ser to Arg at the position corresponding to amino acid 39 of SEQ ID NO:3.
[0029] The mutation (d) is a substitution or deletion of the amino acid residue at the position corresponding to position 46 of the amino acid sequence of SEQ ID NO: 3 with another amino acid residue, or an insertion of another amino acid residue before or after the position. At the position corresponding to position 46, the amino acid residue before substitution is preferably Ala, and the other amino acid residue substituted therewith is preferably Asp, Glu, Lys or Arg, more preferably Asp, Glu or Arg. Preferably, the mutation (d) is 1 ) Ala to Asp substitution at the position corresponding to position 46 of the amino acid sequence of SEQ ID NO:3; 2 ) Ala to Glu substitution at the position corresponding to position 46 of the amino acid sequence of SEQ ID NO:3; 3 ) a substitution of Ala to Lys at the position corresponding to position 46 of the amino acid sequence of SEQ ID NO:3; or 4 ) Ala to Arg substitution at the position corresponding to position 46 of the amino acid sequence of SEQ ID NO:3.
[0030] The mutation (e) is a substitution or deletion of an amino acid residue at at least one position selected from the group consisting of positions corresponding to positions 4, 49, and 58 of the amino acid sequence of SEQ ID NO: 3 with another amino acid residue, or an insertion of another amino acid residue before or after the position. The deleted amino acid residue at positions corresponding to positions 4, 49, and 58 is preferably Lys. At positions corresponding to positions 4, 49, and 58, the amino acid residue before substitution is preferably Lys, and the other amino acid residue substituted therewith is preferably Arg. The mutation (e) may be a single mutation of an amino acid residue at positions corresponding to positions 4, 49, or 58 of the amino acid sequence of SEQ ID NO: 3, or may be a multiple mutation in which two or three of the amino acid residues at positions corresponding to positions 4, 49, and 58 are mutated. For example, the mutation (e) may be a deletion or substitution of a single amino acid residue at a position corresponding to position 4, 49, or 58 of the amino acid sequence of SEQ ID NO: 3, but may also be a multiple mutation in which two or three of the amino acid residues at positions corresponding to positions 4, 49, or 58 are deleted or substituted. Preferably, the mutation (e) is 1 ) deletion of Lys at the position corresponding to position 4 of the amino acid sequence of SEQ ID NO:3; 2 ) a substitution of Lys to Arg at the position corresponding to position 49 of the amino acid sequence of SEQ ID NO:3; 3 ) a deletion of Lys at the position corresponding to position 58 of the amino acid sequence of SEQ ID NO:3, or 4 ) A substitution of Lys to Arg at the position corresponding to position 58 of the amino acid sequence of SEQ ID NO:3.
[0031] The mutation in (f) is a substitution or deletion of the amino acid residue at the position corresponding to position 23 of the amino acid sequence of SEQ ID NO: 3 with another amino acid residue, or an insertion of another amino acid residue before or after the position. At the position corresponding to position 23, the amino acid residue before substitution is preferably Thr, and the other amino acid residue substituted therewith is preferably Arg, Leu, or Ser. Preferably, the mutation in (f) is 1) a substitution of Thr with Arg at the position corresponding to position 23 of the amino acid sequence of SEQ ID NO:3; 2 ) a substitution of Thr to Leu at the position corresponding to position 23 of the amino acid sequence of SEQ ID NO:3, or 3 ) A substitution of Thr to Ser at the position corresponding to amino acid 23 of the amino acid sequence of SEQ ID NO:3.
[0032] In a preferred embodiment, the mutant immunoglobulin-binding domain of the present invention is produced by introducing at least one mutation selected from the group consisting of (a) to (f) into a polypeptide chain consisting of the amino acid sequence of any of SEQ ID NOs: 1 to 6. In another preferred embodiment, the mutant immunoglobulin-binding domain of the present invention is produced by introducing at least one mutation selected from the group consisting of (a) to (f) into a polypeptide chain consisting of an amino acid sequence having at least 85% identity to the amino acid sequence of any of SEQ ID NOs: 1 to 6 and having immunoglobulin-binding activity. In a more preferred embodiment, the mutant immunoglobulin-binding domain of the present invention is produced by introducing at least one mutation selected from the group consisting of (a) to (f) into a polypeptide chain consisting of any one of the amino acid sequences of SEQ ID NOs: 1 to 3. In another more preferred embodiment, the mutant immunoglobulin-binding domain of the present invention is produced by introducing at least one mutation selected from the group consisting of (a) to (f) into a polypeptide chain having an amino acid sequence that has at least 85% identity to any of the amino acid sequences of SEQ ID NOs: 1 to 3 and has immunoglobulin-binding activity. In a further preferred embodiment, the mutant immunoglobulin-binding domain of the present invention is produced by introducing at least one mutation selected from the group consisting of (a) to (f) into a polypeptide chain consisting of the amino acid sequence of SEQ ID NO: 3, or a polypeptide chain consisting of an amino acid sequence having at least 85% identity thereto and having immunoglobulin-binding activity. The mutations to be introduced may be any one of the mutations (a) to (f) or a combination of two or more of the mutations (i.e., mutations of amino acid residues at positions corresponding to at least two of positions 3, 6, 11, 24, 25, 39, 46, 4, 49, 58, and 23 of the amino acid sequence of SEQ ID NO: 3), and preferably any one of the mutations (a) to (f) above. 1 ), (a 2 ), (a 3 ), (a 4 ), (a 5 ), (a 6 ), (a 7 ), (a 8 ), (a 9 ), (a 10 ), (a 11 ), (a 12 ), (a 13 ), (a 14 ), (a 15 ), (a 16 ), (a 17 ), (a 18 ), (a 19 ), (a 20 ), (a 21 ), (a 22 ), (b 1 ), (b 2 ), (c 1 ), (c 2 ), (d 1 ), (d 2 ), (d 3 ), (d 4 ), (e 1 ), (e 2 ), (e 3 ), (e 4 ), (f 1 ), (f 2 ) and (f 3 ) is at least one type of mutation selected from the group consisting of ), or a combination of two or more types of mutations. Examples of the combination of two or more types of mutations include the above-mentioned (a 23 )~(a 28 Another example of the combination of two or more mutations is the above-mentioned (a 1 )~(a 28 ) and one of the above (b 1 )~(f 3) and preferably any one or more of the above (a 1 )~(a 22 ) and one of the above (e 1 )~(f 3 ) is preferably a combination of any one or more of the above (a 7 )~(a 22 ) and one of the above (e 2 ), (e 4 ), (f 1 ), (f 2 ) and (f 3 ) is preferably a combination of any one or more of the above (a 7 ) and the above (e 2 ), (e 4 ), (f 1 ), (f 2 ) and (f 3 ), more preferably in combination with any one or more of the following: (g 1 ) above (a 7 ) and (f 1 ) combination; (g 2 ) above (a 7 ) and (f 2 ) combination; (g 3 ) above (a 7 ) and (f 3 ) combination; (g 4 ) above (a 7 ) and (e 2 ) combination; (g 5 ) above (a 7 ) and (e 4 ) combination; (g 6 ) above (a 7 ) and (f 1 ) and (e 2 ) combination; (g 7 ) above (a 7 ) and (f 2 ) and (e 2 ) combination; and (g8 ) above (a 7 ) and (f 3 ) and (e 2 ) combination.
[0033] In a preferred embodiment, the at least one mutation selected from the group consisting of (a) to (f) is 1 ), (a 2 ), (a 3 ), (a 4 ), (a 5 ), (a 6 ), (a 7 ), (a 8 ), (a 9 ), (a 10 ), (a 11 ), (a 12 ), (a 13 ), (a 14 ), (a 15 ), (a 16 ), (a 17 ), (a 18 ), (a 19 ), (a 20 ), (a 21 ), (a 22 ), (a 23 ), (a 24 ), (a 25 ), (a 26 ), (a 27 ), (a 28 ), (b 1 ), (b 2 ), (c 1 ), (c 2 ), (d 1 ), (d 2 ), (d 3 ), (d 4 ), (e 1 ), (e 2 ), (e 3 ), (e 4 ), (f 1 ), (f 2 ), (f 3 ), (g 1 ), (g 2 ), (g 3 ), (g 4 ), (g 5 ), (g 6 ), (g7 ), or (g 8 In another example, the at least one mutation selected from the group consisting of (a) to (f) is 1 )~(g 8 ), but the (a 1 )~(g 8 In yet another embodiment, the at least one mutation selected from the group consisting of (a) to (f) does not include any other mutation among the mutations in (e 2 ), (e 3 ) or (e 4 ) single mutation only, or (e 2 ) and (e 3 ) or (e 2 ) and (e 4 ) double mutations only.
[0034] An example of a method for mutating a parent domain is a method for introducing a mutation into a polynucleotide encoding the parent domain so as to cause a desired amino acid residue to be substituted, deleted, inserted, etc. Specific techniques for introducing a mutation into a polynucleotide include site-specific mutagenesis, homologous recombination, and splicing by overlap extension (SOE)-PCR (Gene, 1989, 77:61-68), and the detailed procedures for these are well known to those skilled in the art.
[0035] The produced mutant immunoglobulin-binding domain of the present invention has immunoglobulin-binding activity and functions as an immunoglobulin-binding domain. Furthermore, the mutant immunoglobulin-binding domain of the present invention has improved alkali resistance compared to the domain before mutation (parent domain). Therefore, these mutant immunoglobulin-binding domains of the present invention can be suitably used as affinity ligands.
[0036] A preferred example of the mutant immunoglobulin-binding domain of the present invention obtained by the above procedure is a polypeptide chain having immunoglobulin-binding activity, which consists of an amino acid sequence that has at least 85% identity with any of the amino acid sequences of SEQ ID NOs: 1 to 6 and has at least one mutation selected from the group consisting of (a) to (f) above. More preferred examples of the mutant immunoglobulin-binding domain of the present invention include a polypeptide chain having immunoglobulin-binding activity, which consists of an amino acid sequence that has at least 85% identity with any of the amino acid sequences of SEQ ID NOs: 1 to 3 and has at least one mutation selected from the group consisting of (a) to (f) above. Further preferred examples of the mutant immunoglobulin-binding domain of the present invention include polypeptide chains having immunoglobulin-binding activity, which consist of an amino acid sequence that has at least 85% identity with the amino acid sequence of SEQ ID NO: 3 and has at least one mutation selected from the group consisting of (a) to (f) above. At least one mutation selected from the group consisting of (a) to (f) is preferably the above-mentioned (a 1 ), (a 2 ), (a 3 ), (a 4 ), (a 5 ), (a 6 ), (a 7 ), (a 8 ), (a 9 ), (a 10 ), (a 11 ), (a 12 ), (a 13 ), (a 14 ), (a 15 ), (a 16 ), (a 17 ), (a 18 ), (a 19 ), (a 20 ), (a 21 ), (a 22 ), (b 1 ), (b 2 ), (c 1 ), (c 2 ), (d 1 ), (d 2 ), (d3 ), (d 4 ), (e 1 ), (e 2 ), (e 3 ), (e 4 ), (f 1 ), (f 2 ) and (f 3 ), and more preferably, the above (a 1 ), (a 2 ), (a 3 ), (a 4 ), (a 5 ), (a 6 ), (a 7 ), (a 8 ), (a 9 ), (a 10 ), (a 11 ), (a 12 ), (a 13 ), (a 14 ), (a 15 ), (a 16 ), (a 17 ), (a 18 ), (a 19 ), (a 20 ), (a 21 ), (a 22 ), (a 23 ), (a 24 ), (a 25 ), (a 26 ), (a 27 ), (a 28 ), (b 1 ), (b 2 ), (c 1 ), (c 2 ), (d 1 ), (d 2 ), (d 3 ), (d 4 ), (e 1 ), (e 2 ), (e 3 ), (e 4 ), (f 1 ), (f 2 ), (f 3 ), (g 1 ), (g 2 ), (g 3 ), (g 4 ), (g 5 ), (g6 ), (g 7 ), or (g 8 In another example, the at least one mutation selected from the group consisting of (a) to (f) is 1 )~(g 8 ), but the (a 1 )~(g 8 In yet another embodiment, the at least one mutation selected from the group consisting of (a) to (f) does not include any other mutation among the mutations in (e 2 ), (e 3 ) or (e 4 ) single mutation only, or (e 2 ) and (e 3 ) or (e 2 ) and (e 4 ) double mutations only.
[0037] Alternatively, preferred examples of the mutant immunoglobulin-binding domain of the present invention include those having at least 85% identity with any of the amino acid sequences of SEQ ID NOs: 1 to 6 and having the following structure (A 1 )~(F 3 ): (A 1 ) Gln at the position corresponding to position 3 of the amino acid sequence of SEQ ID NO:3; (A 2 ) Ala at the position corresponding to position 3 of the amino acid sequence of SEQ ID NO:3; (A 3 ) Asp at the position corresponding to position 3 of the amino acid sequence of SEQ ID NO:3; (A 4 ) Gln at the position corresponding to position 6 of the amino acid sequence of SEQ ID NO:3; (A 5 ) Ala at the position corresponding to position 6 of the amino acid sequence of SEQ ID NO:3; (A 6 ) Asp at the position corresponding to position 6 of the amino acid sequence of SEQ ID NO:3; (A 7 ) Gln at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 8) Ala at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 9 ) Arg at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 10 ) Asp at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 11 ) Cys at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 12 ) Glu at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 13 ) His at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 14 ) Ile at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 15 ) Leu at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 16 ) Lys at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 17 ) Met at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 18 ) Phe at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 19 ) Thr at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 20 ) Trp at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 21 ) Tyr at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 22 ) Val at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (B 1 ) Asp at a position corresponding to position 24 of the amino acid sequence of SEQ ID NO:3; (B 2 ) Asp at the position corresponding to position 25 of the amino acid sequence of SEQ ID NO:3; (C 1 ) Lys at a position corresponding to position 39 of the amino acid sequence of SEQ ID NO:3; (C 2 ) Arg at a position corresponding to position 39 of the amino acid sequence of SEQ ID NO:3; (D 1 ) Asp at a position corresponding to position 46 of the amino acid sequence of SEQ ID NO:3; (D 2 ) Glu at a position corresponding to position 46 of the amino acid sequence of SEQ ID NO:3; (D 3 ) Lys at a position corresponding to position 46 of the amino acid sequence of SEQ ID NO:3; (D 4 ) Arg at a position corresponding to position 46 of the amino acid sequence of SEQ ID NO:3; (E 1 ) deletion of Lys at the position corresponding to position 4 of the amino acid sequence of SEQ ID NO:3; (E 2 ) Arg at a position corresponding to position 49 of the amino acid sequence of SEQ ID NO:3; (E 3 ) deletion of Lys at the position corresponding to position 58 of the amino acid sequence of SEQ ID NO:3; (E 4 ) Arg at a position corresponding to position 58 of the amino acid sequence of SEQ ID NO:3; (F 1 ) Arg at a position corresponding to position 23 of the amino acid sequence of SEQ ID NO:3; (F 2 ) Leu at a position corresponding to position 23 of the amino acid sequence of SEQ ID NO:3; and (F 3 ) Ser at the position corresponding to position 23 of the amino acid sequence of SEQ ID NO:3; and a polypeptide chain having an amino acid sequence having at least one amino acid residue selected from the group consisting of: or a combination of two or more of these amino acid residues. The amino acid sequence having at least 85% identity with any of the amino acid sequences of SEQ ID NOs: 1 to 6 is preferably an amino acid sequence having at least 85% identity with any of the amino acid sequences of SEQ ID NOs: 1 to 3, and more preferably an amino acid sequence having at least 85% identity with the amino acid sequence of SEQ ID NO: 3. Examples of the combination of two or more amino acid residues include the following (A 23 )~(A 28 ) are: (A 23 ) Gln at positions corresponding to positions 3, 6 and 11 of the amino acid sequence of SEQ ID NO:3; (A 24 ) Ala at the position corresponding to position 3, Asp at the position corresponding to position 6, and Gln at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 25 ) Asp at a position corresponding to position 3 and Gln at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 26 ) Asp at a position corresponding to position 6 and Gln at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 27 ) Asp at the position corresponding to position 3, Asp at the position corresponding to position 6, and Gln at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 28 ) Ala at the position corresponding to position 3, Asp at the position corresponding to position 6, and Gln at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3. Other examples of the combination of two or more types of amino acid residues include the above-mentioned 1 )~(A 28 ) and one of the above (B 1 )~(F 3 ) and preferably any one or more of the above (A 1 )~(A 22) and one of the above (E 1 )~(F 3 ) is preferably a combination of any one or more of the above (A 7 )~(A 22 ) and one of the above (E 2 ), (E 4 ), (F 1 ), (F 2 ) and (F 3 ) and more preferably any one or more of the above (A 7 ) and the above (E 2 ), (E 4 ), (F 1 ), (F 2 ) and (F 3 ), more preferably in combination with any one or more of the following: (G 1 ) Above (A 7 ) and (F 1 ); (G 2 ) Above (A 7 ) and (F 2 ); (G 3 ) Above (A 7 ) and (F 3 ); (G 4 ) Above (A 7 ) and (E 2 ); (G 5 ) Above (A 7 ) and (E 4 ); (G 6 ) Above (A 7 ), (F 1 ) and (E 2 ); (G 7 ) Above (A 7 ), (F 2 ) and (E 2 ); or (G 8 ) Above (A 7 ), (F 3 ) and (E 2 ).
[0038] Alternatively, a more preferred example of the mutant immunoglobulin-binding domain of the present invention is one that has at least 85% identity with any of the amino acid sequences of SEQ ID NOs: 1 to 6 and has the following structure: (A 1 ) Gln at the position corresponding to position 3 of the amino acid sequence of SEQ ID NO:3; (A 2 ) Ala at the position corresponding to position 3 of the amino acid sequence of SEQ ID NO:3; (A 3 ) Asp at the position corresponding to position 3 of the amino acid sequence of SEQ ID NO:3; (A 4 ) Gln at the position corresponding to position 6 of the amino acid sequence of SEQ ID NO:3; (A 5 ) Ala at the position corresponding to position 6 of the amino acid sequence of SEQ ID NO:3; (A 6 ) Asp at the position corresponding to position 6 of the amino acid sequence of SEQ ID NO:3; (A 7 ) Gln at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 8 ) Ala at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 9 ) Arg at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 10 ) Asp at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 11 ) Cys at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 12 ) Glu at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 13 ) His at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 14 ) Ile at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 15 ) Leu at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A16 ) Lys at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 17 ) Met at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 18 ) Phe at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 19 ) Thr at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 20 ) Trp at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 21 ) Tyr at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 22 ) Val at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 23 ) Gln at positions corresponding to positions 3, 6 and 11 of the amino acid sequence of SEQ ID NO:3; (A 24 ) Ala at a position corresponding to position 3 and Gln at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 25 ) Asp at a position corresponding to position 3 and Gln at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 26 ) Asp at a position corresponding to position 6 and Gln at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 27 ) Asp at the position corresponding to position 3, Asp at the position corresponding to position 6, and Gln at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (A 28 ) Ala at the position corresponding to position 3, Asp at the position corresponding to position 6, and Gln at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (B 1 ) Asp at a position corresponding to position 24 of the amino acid sequence of SEQ ID NO:3; (B 2) Asp at the position corresponding to position 25 of the amino acid sequence of SEQ ID NO:3; (C 1 ) Lys at a position corresponding to position 39 of the amino acid sequence of SEQ ID NO:3; (C 2 ) Arg at a position corresponding to position 39 of the amino acid sequence of SEQ ID NO:3; (D 1 ) Asp at a position corresponding to position 46 of the amino acid sequence of SEQ ID NO:3; (D 2 ) Glu at a position corresponding to position 46 of the amino acid sequence of SEQ ID NO:3; (D 3 ) Lys at a position corresponding to position 46 of the amino acid sequence of SEQ ID NO:3; (D 4 ) Arg at a position corresponding to position 46 of the amino acid sequence of SEQ ID NO:3; (E 1 ) deletion of Lys at the position corresponding to position 4 of the amino acid sequence of SEQ ID NO:3; (E 2 ) Arg at a position corresponding to position 49 of the amino acid sequence of SEQ ID NO:3; (E 3 ) deletion of Lys at the position corresponding to position 58 of the amino acid sequence of SEQ ID NO:3; (E 4 ) Arg at a position corresponding to position 58 of the amino acid sequence of SEQ ID NO:3; (F 1 ) Arg at a position corresponding to position 23 of the amino acid sequence of SEQ ID NO:3; (F 2 ) Leu at a position corresponding to position 23 of the amino acid sequence of SEQ ID NO:3; (F 3 ) Ser at a position corresponding to position 23 of the amino acid sequence of SEQ ID NO:3; (G 1 ) Above (A 7 ) and (F 1 ); (G 2 ) Above (A 7 ) and (F 2 ); (G 3 ) Above (A 7) and (F 3 ); (G 4 ) Above (A 7 ) and (E 2 ); (G 5 ) Above (A 7 ) and (E 4 ); (G 6 ) Above (A 7 ), (F 1 ) and (E 2 ); (G 7 ) Above (A 7 ), (F 2 ) and (E 2 ); or (G 8 ) Above (A 7 ), (F 3 ) and (E 2 ), and the like. The amino acid sequence having at least 85% identity to any of the amino acid sequences of SEQ ID NOs: 1 to 6 is preferably an amino acid sequence having at least 85% identity to any of the amino acid sequences of SEQ ID NOs: 1 to 3, and more preferably an amino acid sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 3. In another example, the mutant immunoglobulin-binding domain of the present invention is a polypeptide chain having an amino acid sequence comprising the above-mentioned (A 1 )~(G 8 ) or a deletion thereof, 1 )~(G 8 In yet another embodiment, the mutant immunoglobulin-binding domain of the present invention does not include any other amino acid residues or deletions among the amino acid residues or deletions of (A 1 )~(F 3 At least one amino acid residue or deletion thereof selected from the group consisting of (E 2 )K49R, (E 3 )ΔK58, or (E 4 ) K58R single mutation, or K49RΔK58, or K49RK58R double mutations.
[0039] In the mutant immunoglobulin-binding domain of the present invention, the amino acid sequence having at least 85% identity with the amino acid sequence of any one of SEQ ID NOs: 1 to 6 may be an amino acid sequence having at least 85% identity with the amino acid sequence of any one of SEQ ID NOs: 57 to 62. In addition, in the mutant immunoglobulin-binding domain of the present invention, the amino acid sequence having at least 85% identity with the amino acid sequence of any one of SEQ ID NOs: 1 to 3 may be an amino acid sequence having at least 85% identity with the amino acid sequence of any one of SEQ ID NOs: 57 to 59. However, the mutant immunoglobulin-binding domain of the present invention consisting of an amino acid sequence having at least 85% identity with the amino acid sequence of SEQ ID NOs: 57 to 62 may not contain any of the above mutations (a) to (f) in the amino acid residues at positions corresponding to positions 3 and 4 of the amino acid sequence of SEQ ID NO: 3.
[0040] Preferably, a mutant immunoglobulin binding domain of the invention comprises a Val at a position corresponding to position 1 of the amino acid sequence of SEQ ID NO:3 and / or an Ala at a position corresponding to position 29 of the amino acid sequence of SEQ ID NO:3.
[0041] Further preferred examples of the mutant immunoglobulin-binding domain of the present invention include a polypeptide chain consisting of any of the amino acid sequences of SEQ ID NOs: 7 to 53.
[0042] The immunoglobulin-binding protein of the present invention may contain one or more of the mutant immunoglobulin-binding domains of the present invention described above. Preferably, the immunoglobulin-binding protein of the present invention contains two or more, more preferably three or more, even more preferably four or more, even more preferably five or more, and even more preferably six or more of the mutant immunoglobulin-binding domains of the present invention. On the other hand, the immunoglobulin-binding protein of the present invention contains preferably 12 or less, more preferably eight or less, and even more preferably seven or less of the mutant immunoglobulin-binding domains of the present invention. For example, the immunoglobulin-binding protein of the present invention contains preferably 2 to 12, more preferably 3 to 8, and even more preferably 4 to 7 of the mutant immunoglobulin-binding domains of the present invention. When the immunoglobulin-binding protein of the present invention contains two or more mutant immunoglobulin-binding domains of the present invention, the mutant immunoglobulin-binding domains may be of the same type or different types, but are preferably of the same type.
[0043] The immunoglobulin-binding protein of the present invention may contain other immunoglobulin-binding domains other than the above-mentioned mutant immunoglobulin-binding domains of the present invention. Examples of such other domains include naturally occurring SpA immunoglobulin-binding domains (e.g., the B domain, Z domain, C domain, or D domain of SpA) or mutants thereof other than the mutant immunoglobulin-binding domains of the present invention.
[0044] A preferred example of the immunoglobulin-binding protein of the present invention is a polypeptide in which two or more amino acid sequences of the mutant immunoglobulin-binding domains of the present invention are linked in a linear chain. The number of the mutant immunoglobulin-binding domains contained in the immunoglobulin-binding protein of the present invention is preferably 2 to 12, more preferably 3 to 8, and even more preferably 4 to 7. A more preferred example of the immunoglobulin-binding protein of the present invention is a polypeptide consisting of an amino acid sequence in which two or more amino acid sequences selected from the amino acid sequences of SEQ ID NOs: 7 to 53 are linked in a linear chain. A further preferred example of the immunoglobulin-binding protein of the present invention is a polypeptide consisting of an amino acid sequence in which 2 to 12, more preferably 3 to 8, and even more preferably 4 to 7 amino acid sequences selected from the amino acid sequences of SEQ ID NOs: 7 to 53 are linked in a linear chain. A further preferred example is a polypeptide consisting of an amino acid sequence in which 2 to 12, more preferably 3 to 8, and even more preferably 4 to 7 amino acid sequences of any of SEQ ID NOs: 7 to 53 are linked in a linear chain. However, preferred examples of the protein of the present invention are not limited to these. In the present invention, the term "linearly linked" amino acid sequences refers to a structure in which two or more amino acid sequences are linked in series with or without a linker. For example, when a linker is used, "linearly linked" refers to a structure in which the C-terminus of one amino acid sequence and the N-terminus of another amino acid sequence are linked in series with a linker, whereas when no linker is used, "linearly linked" refers to a structure in which the C-terminus of one amino acid sequence and the N-terminus of another amino acid sequence are linked in series by a peptide bond.
[0045] From the viewpoints of increasing the amount of the immunoglobulin-binding protein of the present invention immobilized on a carrier, increasing the number of binding sites on the carrier, increasing the antibody binding capacity, etc., any amino acid residue or peptide may be added or inserted at one or more positions at the N-terminus, C-terminus, and between domains of the immunoglobulin-binding domain contained in the immunoglobulin-binding protein of the present invention. Preferred examples of the amino acid residue or peptide to be added or inserted include Cys, Lys, Pro, (Pro)m, (Ala-Pro)n, and (Glu-Ala-Ala-Ala-Lys)p (m is an integer of 2 to 300, preferably an integer of 12 to 24, n is an integer of 4 or more, preferably an integer of 4 to 10, and p is an integer of 2 or more, preferably an integer of 2 to 6).
[0046] 2. Production of Immunoglobulin-binding Proteins The immunoglobulin-binding protein of the present invention can be produced by a method known in the art, such as a chemical synthesis method based on the amino acid sequence or a recombinant method. For example, the immunoglobulin-binding protein of the present invention can be produced by utilizing known gene recombination techniques described in Current Protocols In Molecular Biology by Frederick M. Ausbel et al., Molecular Cloning edited by Sambrook et al. (Cold Spring Harbor Laboratory Press, 3rd edition, 2001), etc. That is, an expression vector containing a polynucleotide encoding the immunoglobulin-binding protein of the present invention is transformed into a host such as Escherichia coli, and the resulting recombinant is cultured in an appropriate liquid medium, whereby the target protein can be obtained in large quantities and economically from the cultured cells. As a preferred expression vector, any known vector capable of replicating in a host cell can be used, and examples thereof include the plasmids described in U.S. Pat. No. 5,151,350 and the plasmids described in Molecular Cloning edited by Sambrook et al. (Cold Spring Harbor Laboratory Press, 3rd edition, 2001), etc. In addition, the host for transformation is not particularly limited, and known hosts used for expressing recombinant proteins, such as bacteria such as E. coli, fungi, insect cells, and mammalian cells, can be used. In order to transform a host by introducing a nucleic acid into the host, any method known in the art may be used depending on the host, and for example, known methods described in Molecular Cloning edited by Sambrook et al. (Cold Spring Harbor Laboratory Press, 3rd edition, 2001) can be used. Methods for culturing the obtained transformant (preferably cells such as bacteria) and recovering the expressed protein are well known to those skilled in the art. Alternatively, the immunoglobulin-binding protein of the present invention may be expressed using a cell-free protein synthesis system.
[0047] Therefore, the present invention also provides polynucleotides (such as DNA) encoding the immunoglobulin-binding proteins of the present invention, vectors containing them, and transformants containing them.
[0048] 3. Affinity Supports The immunoglobulin-binding protein of the present invention can be used as an affinity ligand. By immobilizing the immunoglobulin-binding protein of the present invention on a solid-phase support, an affinity support can be produced using the immunoglobulin-binding protein of the present invention as a ligand. The affinity support is a support using the immunoglobulin-binding protein of the present invention as a ligand, and has immunoglobulin-binding activity. Furthermore, the affinity support has improved alkali resistance compared to supports using wild-type protein A or a domain thereof as a ligand.
[0049] The shape of the solid phase carrier included in the affinity carrier of the present invention can be any shape such as particles, membranes, plates, tubes, needles, fibers, etc. The carriers can be porous or non-porous. These carriers can be used as packed beds or in suspension form. Suspension forms include what are known as expanded beds and pure suspensions, in which particles can move freely. In the case of monoliths, packed beds and fluidized beds, the separation procedure generally follows conventional chromatographic methods using concentration gradients. In the case of pure suspensions, a batch method is used. Preferably, the carrier is a packing material. Alternatively, the carrier can be in the form of a chip, capillary, or filter.
[0050] In one embodiment, when the solid phase carrier is a particle, the particle size is preferably 20 μm or more and 200 μm or less. For example, when the carrier is a synthetic polymer, the particle size is preferably 20 μm or more, more preferably 30 μm or more, and preferably 100 μm or less, more preferably 80 μm or less, for example, preferably 20 to 100 μm, more preferably 30 to 80 μm. For example, when the carrier is a polysaccharide, the particle size is preferably 50 μm or more, more preferably 60 μm or more, and preferably 200 μm or less, more preferably 150 μm or less, for example, preferably 50 to 200 μm, more preferably 60 to 150 μm. If the particle size is less than 20 μm, the column pressure increases under high flow rate, making it unsuitable for practical use. If the particle size exceeds 200 μm, the amount of immunoglobulin bound to the affinity carrier (binding capacity) may be poor. In this specification, the term "particle size" refers to the volume average particle size measured by a laser diffraction method in accordance with ISO 13320 and JIS Z 8825-1. Specifically, the term refers to the average particle size obtained by measuring the particle size distribution by a laser scattering diffraction method particle size distribution measuring device (e.g., LS 13 320 (Beckman Coulter, Inc., etc.) and measuring the volume-based particle size distribution using Fluid RIReal 1.333, Sample RIReal 1.54 Imaginary 0, etc. as an optical model.
[0051] In one embodiment, the solid support is porous, preferably 50 mm. 2 / g or more, more preferably 80m 2 / g or more, and preferably 150m 2 / g or less, more preferably 130m 2 / g or less, for example, preferably 50 to 150 m 2 / g, more preferably 80 to 130m 2 / g, where the specific surface area is 50 m 2 If it is less than 150m / g, the binding capacity may be poor. 2If it exceeds 1 / g, the strength of the carrier is poor and the carrier may be destroyed at a high flow rate, resulting in an increase in column pressure. Note that the "specific surface area" in this specification is a value obtained by dividing the surface area of pores having a pore diameter of 10 to 5000 nm obtained by a mercury porosimeter by the dry weight of the particles.
[0052] In one embodiment, the solid phase carrier has a volume average pore diameter of preferably 100 nm or more and 1500 nm or less. For example, when the carrier is a synthetic polymer, the volume average pore diameter is preferably 100 nm or more, more preferably 200 nm or more, and preferably 400 nm or less, more preferably 300 nm or less, for example, preferably 100 to 400 nm, and more preferably 200 to 300 nm. For example, when the carrier is a polysaccharide, the volume average pore diameter is preferably 500 nm or more, more preferably 800 nm or more, and preferably 1500 nm or less, more preferably 1400 nm or less, for example, preferably 500 to 1500 nm, and more preferably 800 to 1400 nm. Here, when the volume average pore diameter is less than 100 nm, the binding capacity may decrease significantly under high flow rate, while when it exceeds 1500 nm, the binding capacity may decrease regardless of the flow rate. In this specification, the "volume average pore diameter" refers to the volume average pore diameter of pores having a pore diameter of 10 to 5000 nm obtained by a mercury porosimeter.
[0053] When the solid phase carrier satisfies the above-mentioned ranges of particle size, specific surface area, and pore size distribution, the balance between the gaps between the particles and the relatively large pore size within the particles that serve as the flow path for the solution to be purified, and the binding surface area for the molecules to be purified is optimized, and the binding capacity at high flow rates is maintained at a high level.
[0054] The material of the solid phase carrier is, for example, a polymer having a hydrophilic surface, and for example, a hydroxyl group (-OH), a carboxyl group (-COOH), an aminocarbonyl group (-CONH ... 2 , or N-substituted), amino group (-NH 2, or substituted), or a polymer having an oligo or polyethyleneoxy group. In one embodiment, the polymer may be a synthetic polymer such as polymethacrylate, polyacrylamide, polystyrene, polyvinyl alcohol, etc., and preferably a synthetic polymer such as a copolymer crosslinked with a polyfunctional monomer such as a polyfunctional (meth)acrylate or divinylbenzene. Such a synthetic polymer is easily produced by a known method (see, for example, the method described in J. MATER. CHEM 1991, 1(3):371-374). Alternatively, a commercially available product such as Toyopearl (Tosoh Corporation) may be used. In another embodiment, the polymer is a polysaccharide such as dextran, starch, cellulose, pullulan, agarose, etc. Such a polysaccharide is easily produced by a known method (see, for example, the method described in Japanese Patent No. 4081143). Alternatively, a commercially available product such as Sepharose (GE Healthcare Biosciences) may be used. In another embodiment, the polymer may be an inorganic carrier such as silica or zirconium oxide.
[0055] In one embodiment, a specific example of the porous particles used as the solid phase support is, for example, a copolymer of 20 to 50% by mass of a crosslinkable vinyl monomer, 3 to 80% by mass of an epoxy group-containing vinyl monomer, and 20 to 80% by mass of a diol group-containing vinyl monomer, and has a particle size of 20 to 80 μm and a specific surface area of 50 to 150 m. 2 / g and a volume average pore diameter of 100 to 400 nm.
[0056] The intrusion volume (pore volume) of pores with a pore diameter of 10 to 5000 nm when the solid phase carrier is measured by a mercury porosimeter is preferably 1.3 mL / g or more and 7.0 mL / g or less. For example, when the carrier is a synthetic polymer, the pore volume is preferably 1.3 mL / g or more and preferably 7.0 mL / g or less, more preferably 5.0 mL / g or less, and even more preferably 2.5 mL / g or less, for example, preferably 1.3 to 7.0 mL / g, more preferably 1.3 to 5.0 mL / g, and even more preferably 1.3 to 2.5 mL / g. For example, when the carrier is a polysaccharide, the pore volume is preferably 3.0 to 6.0 mL / g.
[0057] The method of binding the ligand (i.e., the immunoglobulin-binding protein of the present invention) to the solid phase carrier can be carried out by using a general method for immobilizing a protein on a carrier. For example, a method of using a carrier having a carboxy group, activating the carboxy group with N-hydroxysuccinimide and reacting it with an amino group of a ligand; a method of using a carrier having an amino or carboxy group and reacting it with a carboxy or amino group of a ligand in the presence of a dehydrating condensing agent such as a water-soluble carbodiimide to form an amide bond; a method of using a carrier having a hydroxy group, activating it with a cyanogen halide such as cyanogen bromide and reacting it with an amino group of a ligand; a method of tosylating or tresylating a hydroxy group of a carrier and reacting it with an amino group of a ligand; a method of introducing an epoxy group into a carrier using bisepoxide, epichlorohydrin, or the like and reacting it with an amino group, hydroxyl group, or thiol group of a ligand; a method of using a carrier having an epoxy group and reacting it with an amino group, hydroxyl group, or thiol group of a ligand; and the like. Among the above, the method of binding the ligand via an epoxy group is preferable from the viewpoint of stability in an aqueous solution in which the reaction is carried out.
[0058] The hydroxyl group, which is a ring-opened epoxy group generated by ring-opening of the epoxy group, hydrophilizes the carrier surface, prevents non-specific adsorption of proteins and the like, improves the toughness of the carrier in water, and plays a role in preventing the destruction of the carrier under high flow rates. Therefore, when residual epoxy groups that are not bound to the ligand are present in the carrier after the ligand is immobilized, it is preferable to ring-open the residual epoxy groups. As a method for ring-opening the epoxy groups in the carrier, for example, a method of stirring the carrier in an aqueous solvent with an acid or alkali at room temperature or by heating can be mentioned. In addition, the epoxy groups may be ring-opened with a blocking agent having a mercapto group such as mercaptoethanol or thioglycerol, or a blocking agent having an amino group such as monoethanolamine. A more preferred ring-opened epoxy group is a ring-opened epoxy group obtained by ring-opening the epoxy group contained in the carrier with thioglycerol. Thioglycerol is a raw material that is less toxic than mercaptoethanol and the like. In addition, the epoxy ring-opening group to which thioglycerol is added has the advantages of lower nonspecific adsorption and higher dynamic binding amount than the ring-opening group formed by a blocking agent having an amino group.
[0059] If necessary, a molecule (spacer) of any length may be introduced between the solid phase carrier and the ligand. Examples of the spacer include a polymethylene chain, a polyethylene glycol chain, and sugars.
[0060] Since the affinity carrier of the present invention has a ligand with improved alkaline resistance, its performance does not deteriorate significantly, for example, even when washed under alkaline conditions (e.g., washed with an alkaline solution such as 0.01 to 1.0 M sodium hydroxide) for repeated use of the carrier in affinity purification.
[0061] 4. Method for isolating antibodies or fragments thereof A method for isolating an antibody or a fragment thereof (hereinafter simply referred to as an antibody) according to one embodiment of the present invention will be described. The method for isolating an antibody according to this embodiment preferably comprises a step (first step) of passing an antibody-containing sample through an affinity carrier to which an immunoglobulin-binding protein of the present invention has been immobilized, thereby allowing the antibody to be adsorbed onto the carrier, and a step (second step) of eluting the antibody from the carrier, and preferably further comprises a step (third step) of washing the carrier with an alkaline solution after the second step.
[0062] In the first step, a sample containing an antibody is passed through a column or the like packed with the affinity carrier of the present invention under conditions in which the antibody is adsorbed to the ligand (the immunoglobulin-binding protein of the present invention). In this first step, most of the substances in the sample other than the antibody pass through the column without being adsorbed to the ligand. Thereafter, if necessary, the carrier may be washed with a neutral buffer containing a salt such as NaCl in order to remove some of the substances weakly held by the ligand.
[0063] In the second step, the antibody adsorbed to the ligand is eluted by passing an appropriate buffer solution of pH 2 to 5. The antibody can be isolated from the sample by collecting the eluate.
[0064] In order to increase the purity of the antibody, the antibody contained in the eluate obtained in the second step may be further purified. The antibody can be purified by, for example, cation exchange chromatography, anion exchange chromatography, mixed mode chromatography, hydrophilic interaction chromatography, hydrophobic interaction chromatography, size exclusion chromatography, etc., either alone or in appropriate combination. For example, the antibody can be purified by subjecting the eluate obtained in the second step to cation exchange chromatography and then anion exchange chromatography. The cation exchange chromatography can be performed using SP-Sepharose FF (GE Healthcare Biosciences), BioPro IEX S (YMC), BioPro IEX SmartSep S (YMC), etc. The anion exchange chromatography can be performed using Q-Sepharose FF (GE Healthcare Biosciences), BioPro IEX Q (YMC), BioPro IEX SmartSep Q (YMC), etc.
[0065] In the antibody isolation method according to the present embodiment, the third step is preferably carried out following the second step. In the third step, the affinity carrier is washed with an alkaline solution (CIP washing). Examples of the alkaline solution used in the third step include an aqueous sodium hydroxide solution, an aqueous potassium hydroxide solution, triethylamine, and tetrabutylammonium hydroxide. The molar concentration of the alkaline salt in the alkaline solution used in the third step has a lower limit of 0.001M or more, preferably 0.01M or more, and more preferably 0.1M or more, and an upper limit of 6.0M or less, preferably 4.0M or less, and more preferably 2.0M or less. The pH of the alkaline solution used has a lower limit of pH11.0 or more, preferably pH12.0 or more, and more preferably pH12.5 or more, and an upper limit of pH16.0 or less, preferably pH15.5 or less, and more preferably pH15.0 or less.
[0066] The affinity carrier of the present invention stably retains antibody binding activity even after washing in the above-mentioned third step due to the improved alkaline resistance of the protein ligand, and therefore can be used repeatedly for antibody isolation.
[0067] In one embodiment of the antibody isolation method of the present invention, the isolated antibody is used as an antibody pharmaceutical. Thus, in one embodiment, the present invention provides a method for producing an antibody pharmaceutical using the affinity carrier of the present invention. The procedure of this method is basically the same as the procedure of the antibody isolation method described above, except that a sample containing the desired antibody pharmaceutical is used. EXAMPLES
[0068] The present invention will be described in more detail below with reference to examples. The following description is merely intended to provide a general overview of the present invention, and is not intended to limit the present invention without any particular reason.
[0069] Reference Example 1 Synthesis of Porous Particles (1) 3.58 g of polyvinyl alcohol (PVA-217, manufactured by Kuraray Co., Ltd.) was added to 360 g of pure water, and the mixture was heated and stirred to dissolve the polyvinyl alcohol. After cooling, 0.36 g of sodium dodecyl sulfate (manufactured by Wako Pure Chemical Industries, Ltd.), 0.36 g of sodium sulfate (manufactured by Wako Pure Chemical Industries, Ltd.), and 0.18 g of sodium nitrite (manufactured by Wako Pure Chemical Industries, Ltd.) were added and stirred to prepare an aqueous solution S. (2) A monomer composition consisting of 12.00 g of glycidyl methacrylate (manufactured by Mitsubishi Chemical Corporation) and 1.33 g of divinylbenzene (manufactured by Nippon Steel Chemical Co., Ltd.) was dissolved in 24.43 g of diisobutyl ketone (manufactured by Mitsui Chemicals, Inc.) to prepare a monomer solution. (3) The entire amount of the aqueous solution S obtained in (1) was poured into a separable flask, and a thermometer, stirring blade, and cooling tube were attached. The flask was then placed in a hot water bath and stirring was started under a nitrogen atmosphere. The entire amount of the monomer solution obtained in (2) was poured into the separable flask and heated in the hot water bath. When the internal temperature reached 85°C, 0.53 g of 2,2'-azoisobutyronitrile (manufactured by Wako Pure Chemical Industries, Ltd.) was added. (4) The reaction solution obtained in (3) was stirred for 3 hours while maintaining the temperature at 86°C. The reaction solution was then cooled, filtered, and washed with pure water and ethanol. The washed particles were dispersed in pure water and decanted three times to remove small particles. The particles were then dispersed in pure water to a particle concentration of 10 mass%, to obtain a porous particle (PB) dispersion.
[0070] Example 1: Preparation of immunoglobulin-binding proteins (PrAt-0 to 32) Immunoglobulin-binding proteins PrAt-0 to 32 were obtained. PrAt-0 is an immunoglobulin-binding protein containing a homotetramer in which A1V / G29A mutants (alkaline-resistant mutants; Non-Patent Document 1) of the C domain of protein A (SEQ ID NO: 3) are linked in series via peptide bonds. PrAt-1 to 32 are mutants in which the mutations listed in Table 1 have been introduced into each immunoglobulin-binding domain of PrAt-0.
[0071] [Table 1]
[0072] Expression and purification of PrAt-0 to 32 were carried out as follows. Escherichia coli BL21(DE3) (NEW ENGLAND BIOLABS) was transformed with a plasmid encoding PrAt-0 to 32, and the obtained transformant was cultured in a rich medium at 37°C until the logarithmic growth phase. Thereafter, isopropyl-β-thiogalactopyranoside (Wako Pure Chemical Industries, Ltd.) was added to the medium at a final concentration of 1 mM, and the medium was further cultured at 37°C for 4 hours to express the target protein. The culture solution was then centrifuged to remove the supernatant, and the obtained bacterial cells were disrupted by adding 30 mM Tris buffer at pH 9.5 containing egg white-derived lysozyme (Wako Pure Chemical Industries, Ltd.) and polyoxyethylene (10) octylphenyl ether (Wako Pure Chemical Industries, Ltd.). The recombinant immunoglobulin-binding protein was purified from the resulting cell lysate by cation exchange chromatography (SP-Sepharose FF, GE Healthcare Biosciences) and anion exchange chromatography (Q-Sepharose FF, GE Healthcare Biosciences). The purified immunoglobulin-binding protein was dialyzed against 10 mM citrate buffer, pH 6.0. The purity of the recombinant immunoglobulin-binding protein confirmed by SDS-PAGE was 95% or more.
[0073] Example 2: Preparation of immunoglobulin-binding proteins (PrAp-0 to 41) Immunoglobulin-binding proteins PrAp-0 to 39 were obtained. PrAp-0 is an immunoglobulin-binding protein containing a homopentamer in which A1V / G29A mutants of the C domain of protein A (SEQ ID NO: 3) are linked in series by peptide bonds, and PrAp-21 is an immunoglobulin-binding protein in which cysteine (C) is linked to the C-terminus of a homopentamer in which A1V / G29A mutants of the C domain of protein A (SEQ ID NO: 3) are linked in series by peptide bonds. PrAp-1 to 20 are mutants in which the mutations shown in Table 2 are introduced into each immunoglobulin-binding domain of PrAp-0, and PrAp-22 to 41 are mutants in which the mutations shown in Table 3 are introduced into each immunoglobulin-binding domain of PrAp-21.
[0074] [Table 2]
[0075] [Table 3]
[0076] The expression and purification of PrAp-0–41 were carried out in the same manner as for PrAt-0–32. The purity of the recombinant immunoglobulin-binding proteins confirmed by SDS-PAGE was more than 95%.
[0077] Example 3: Preparation of immunoglobulin-binding proteins (PrAh-0 to 41) Immunoglobulin-binding proteins PrAh-0 to 41 were obtained. PrAh-0 is an immunoglobulin-binding protein containing a homohexamer in which A1V / G29A mutants of the C domain of protein A (SEQ ID NO: 3) are linked in series by peptide bonds, and PrAh-21 is an immunoglobulin-binding protein in which cysteine (C) is linked to the C-terminus of a homohexamer in which A1V / G29A mutants of the C domain of protein A (SEQ ID NO: 3) are linked in series by peptide bonds. PrAh-1 to 20 are mutants in which the mutations shown in Table 4 are introduced into each immunoglobulin-binding domain of PrAh-0, and PrAh-22 to 41 are mutants in which the mutations shown in Table 5 are introduced into each immunoglobulin-binding domain of PrAh-21.
[0078] [Table 4]
[0079] [Table 5]
[0080] The expression and purification of PrAh-0–41 were carried out in the same manner as for PrAt-0–32. The purity of the recombinant immunoglobulin-binding proteins confirmed by SDS-PAGE was more than 95%.
[0081] Example 4 Preparation of Ligand-Immobilized Particles To 8 mg of the porous particles (PB) obtained in Reference Example 1, 450 μL of 0.1 M carbonate buffer (pH 8.8) containing 1.1 M sodium sulfate in which 1.16 mg of PrAt-0 prepared in Example 1 was dissolved was added, and the mixture was shaken at 25 ° C. for 5 hours to bind PrAt-0 to PB. After blocking the epoxy groups remaining on the particles with thioglycerol, the particles were washed with 0.5 M NaOH and 0.1 M citrate buffer (pH 3.2) to obtain ligand-immobilized particles (PrAt-0 / PB). By the same procedure, ligand-immobilized particles (PrAt-1 / PB to PrAt-32 / PB) in which any of PrAt-1 to 32 was bound were obtained. Furthermore, ligand-immobilized particles (PrAp-0 / PB to PrAp-41 / PB) in which any of PrAp-0 to 41 was bound were obtained by the same procedure. Furthermore, ligand-immobilized particles to which any one of PrAh-0 to PrAh-41 was bound (PrAh-0 / PB to PrAh-41 / PB) were obtained by a similar procedure.
[0082] Example 5: Preparation of immunoglobulin-binding proteins (PrAs-0 to 22) Immunoglobulin-binding proteins PrAs-0 to 22 were obtained. PrAs-0 is an immunoglobulin-binding protein in which a six-repeated histidine tag (HHHHHH sequence) is linked to the N-terminus of the A1V / G29A mutant of the C domain of protein A (SEQ ID NO: 3). PrAs-1 to 22 are mutants in which the mutations listed in Table 6 have been introduced into each immunoglobulin-binding domain of PrAs-0.
[0083] [Table 6]
[0084] Expression and purification of PrAs-0–22 were performed in the same manner as for PrAt-0–32, except that the recombinant immunoglobulin-binding proteins were purified by affinity chromatography (HisTrap FF, GE Healthcare Biosciences). The purity of the recombinant immunoglobulin-binding proteins confirmed by SDS-PAGE was 95% or higher.
[0085] Test Example 1 The ligand-immobilized particles PrAt-1 / PB to PrAt-29 / PB containing the mutant domains prepared in Example 4 were evaluated for their relative alkaline resistance to the ligand-immobilized particle PrAt-0 containing the parent domain.
[0086] (1) Measurement of static binding capacity (SBC) 2 mg of ligand-immobilized particles (PrAt-0 / PB) were added with 400 μL of 20 mM phosphate buffer (pH 7.5) containing 2.0 mg of IgG, and incubated for 30 minutes. After washing with 400 μL of 20 mM phosphate buffer (pH 7.5), 400 μL of 50 mM sodium citrate buffer (pH 2.5) was added, and the eluate containing IgG was collected. The amount of IgG in the eluate was calculated by absorbance measurement, and the static binding capacity (SBC) of PrAt-0 / PB was calculated from the amount of eluted IgG and the carrier volume. The SBC of PrAt-1 / PB to PrAt-29 / PB was calculated using the same procedure. The SBC of PrAh-21 / PB to PrAh-41 / PB was also calculated using the same procedure.
[0087] (2) Evaluation of alkaline tolerance: PrAt-1~29 2 mg of ligand-immobilized particles (PrAt-0 / PB) were equilibrated with 1.0 M NaOH and incubated for 24 hours. The particles were then equilibrated with 20 mM phosphate buffer (pH 7.5), after which 400 μL of 20 mM phosphate buffer (pH 7.5) containing 2.0 mg of IgG was added and incubated for 30 minutes. The particles were then washed with 400 μL of 20 mM phosphate buffer (pH 7.5), after which 400 μL of 50 mM sodium citrate buffer (pH 2.5) was added and an eluate containing IgG was collected. The amount of IgG in the eluate was calculated by absorbance measurement, and the SBC of PrAt-0 / PB exposed to alkali was calculated from the amount of eluted IgG and the carrier volume. The SBC of PrAt-1-29 / PB exposed to alkali was calculated using the same procedure. For each ligand-immobilized particle, the relative SBC value after alkali exposure to the SBC obtained in (1) (SBC maintenance rate) was calculated, and then the relative alkali resistance (%) of each ligand-immobilized particle (PrAt-1 to 29) to PrAt-0 was calculated according to the following formula. Relative alkaline tolerance (%) = (SBC maintenance rate of PrAt-N (N = 1 to 29)) / (SBC maintenance rate of PrAt-0) × 100
[0088] (3) Evaluation of alkaline resistance: PrAh-22~38 The SBC of PrAh-21–38 / PB exposed to alkali was determined using the same procedure as in (2), and the relative alkali resistance (%) of PrAh-22–38 to PrAh-21 was calculated.
[0089] (4) Evaluation of alkaline resistance: PrAh-39~41 The ligand-immobilized particles (PrAh-21 / PB and PrAh-39–41 / PB) were equilibrated with 0.5 M NaOH instead of 1.0 M NaOH in the same manner as in (2), and then incubated for 24 hours. The SBC of PrAh-21 and 39–41 / PB exposed to alkali was then determined in the same manner as in (2), and the relative alkali resistance (%) of PrAh-39–41 to PrAh-21 was calculated.
[0090] The results of the SBC measured in (1) and the relative alkaline tolerance measured in (2) to (4) are shown in Tables 7 to 9. The SBC of PrAt-1 to 29 / PB was not significantly different from that of PrAt-0 / PB. On the other hand, the relative alkaline tolerance of PrAt-1 to 29 / PB was improved by 14 to 64% compared to that of PrAt-0 / PB. In addition, the SBC of PrAh-22 to 38 / PB was not significantly different from that of PrAh-21 / PB, while the relative alkaline tolerance was improved by 28 to 69% compared to that of PrAh-21 / PB. Furthermore, the SBC of PrAh-39 to 41 / PB was not significantly different from that of PrAh-21 / PB, while the relative alkaline tolerance was improved by 22 to 26% compared to that of PrAh-21 / PB. These results show that the immunoglobulin-binding proteins of Examples 1 to 3 containing the mutated domain have higher alkaline resistance than before the introduction of the mutation, and can maintain their antibody-binding activity even after being exposed to relatively harsh conditions such as 1.0 M or 0.5 M sodium hydroxide for 24 hours.
[0091] [Table 7]
[0092] [Table 8]
[0093] [Table 9]
[0094] Test Example 2 The immunoglobulin-binding proteins PrAs-1 to PrAs-19 containing the mutated domains prepared in Example 5 were evaluated for their relative alkaline resistance to the immunoglobulin-binding protein PrAs-0 containing the parent domain.
[0095] (1) Preparation of sample solution 0.13 mg of immunoglobulin-binding proteins (PrAs-0 and PrAs-1 to 19) were incubated in a 1.0 M aqueous solution of sodium hydroxide. Immediately after the start of incubation or 24 hours after the start of incubation, the solution was neutralized with 1.0 M citric acid. The neutralized solution was then diluted to a protein concentration of 10 μg / mL using D-PBS buffer containing 0.1% bovine serum albumin (Wako Pure Chemical Industries, Ltd.) and 0.02% Triton X-100 (Wako Pure Chemical Industries, Ltd.) to prepare a sample solution. For these sample solutions, the sample solution in which PrAs-N (N = 0 to 19) was neutralized in sodium hydroxide immediately after the start of incubation was designated PrAs-Na, and the sample solution in which it was neutralized 24 hours after the start of incubation was designated PrAs-Nb.
[0096] (2) Preparation of IgG-binding biosensor 1.0 mg of IgG was reacted with 3.9 μg of EZ-Link NHS-PEG4-Biotin (Thermo Fisher Scientific) to biotinylate the IgG, which was then contacted with a streptavidin biosensor (Pall ForteBio) using an Octet RED 96e system (Pall ForteBio) to immobilize the IgG on the sensor.
[0097] (3) Evaluation of alkaline resistance The IgG-binding biosensor was contacted with the sample solution using the Octet RED 96e system, and the immunoglobulin-binding protein was bound to the IgG on the sensor. The binding rate was determined from the sensorgram, and the relative value of the binding rate of PrAs-Nb to the binding rate of PrAs-Na (binding rate maintenance rate) was calculated. Next, the relative alkaline resistance (%) of each immunoglobulin-binding protein (PrAs-0 to 19) to PrAs-0 was calculated according to the following formula. Relative alkaline resistance (%) = {(PrAs-N (N = 1-19) binding rate maintenance rate) / (PrAs-0 binding rate maintenance rate)} × 100 Binding rate maintenance rate of PrAs-N(N=0-19)=(binding rate of PrAs-N(N=0-19)b) / (binding rate of PrAs-N(N=0-19)a)
[0098] The results of measuring the relative alkaline resistance are shown in Table 10. The relative alkaline resistance of PrAs-17 to 19 was decreased compared to PrAs-0, while the relative alkaline resistance of PrAs-1 to 16 was improved by 60 to 338% compared to PrAs-0. These results demonstrated that the immunoglobulin-binding proteins PrAs-1 to 16 containing the mutated domain have higher alkaline resistance compared to before the introduction of the mutation, and can maintain their antibody binding activity even after being exposed to the relatively harsh conditions of 1.0 M sodium hydroxide for 24 hours.
[0099] [Table 10]
[0100] Test Example 3 The alkaline resistance of the immunoglobulin-binding proteins (PrAs-0 and PrAs-20 to 22) prepared in Example 5 was calculated in the same manner as in Test Example 2, except that they were incubated in a 0.5 M aqueous sodium hydroxide solution. The measurement results of the relative alkaline resistance are shown in Table 11. The relative alkaline resistance of PrAs-20 to 22 was improved by 21 to 31% compared to PrAs-0, indicating that the alkaline resistance is higher than that before the introduction of the mutation.
[0101] [Table 11]
Claims
1. 1. An immunoglobulin binding protein comprising a variant polypeptide chain, The mutant polypeptide chain has an amino acid sequence of SEQ ID NO: 3 or an amino acid sequence having at least 90% identity thereto, and has an immunoglobulin-binding activity, and is characterized by the following: 23 ) to (a 28 ) and (g 1 ) to (g 8 ) wherein any mutation selected from the group consisting of: (a 23 ) substitutions of Asn to Gln at positions corresponding to positions 3, 6, and 11 of the amino acid sequence of SEQ ID NO:3; (a 24 ) a substitution of Asn to Ala at the position corresponding to position 3 of the amino acid sequence of SEQ ID NO:3, and a substitution of Asn to Gln at the position corresponding to position 11; (a 25 ) a substitution of Asn to Asp at a position corresponding to position 3 of the amino acid sequence of SEQ ID NO:3, and a substitution of Asn to Gln at a position corresponding to position 11; (a 26 ) a substitution of Asn to Asp at the position corresponding to position 6 of the amino acid sequence of SEQ ID NO:3, and a substitution of Asn to Gln at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (a 27 ) a substitution of Asn to Asp at a position corresponding to position 3 of the amino acid sequence of SEQ ID NO:3, a substitution of Asn to Asp at a position corresponding to position 6, and a substitution of Asn to Gln at a position corresponding to position 11; (a 28 ) a substitution of Asn to Ala at the position corresponding to position 3, a substitution of Asn to Asp at the position corresponding to position 6, and a substitution of Asn to Gln at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (g 1 ) a substitution of Asn to Gln at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3, and a substitution of Thr to Arg at a position corresponding to position 23 of the amino acid sequence of SEQ ID NO:3; (g 2 ) a substitution of Asn to Gln at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3, and a substitution of Thr to Leu at a position corresponding to position 23 of the amino acid sequence of SEQ ID NO:3; (g 3 ) a substitution of Asn to Gln at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3, and a substitution of Thr to Ser at a position corresponding to position 23 of the amino acid sequence of SEQ ID NO:3; (g 4 ) a substitution of Asn to Gln at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3, and a substitution of Lys to Arg at a position corresponding to position 49 of the amino acid sequence of SEQ ID NO:3; (g 5 ) a substitution of Asn to Gln at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3, and a substitution of Lys to Arg at a position corresponding to position 58 of the amino acid sequence of SEQ ID NO:3; (g 6 ) a substitution of Asn to Gln at a position corresponding to position 11, a substitution of Thr to Arg at a position corresponding to position 23, and a substitution of Lys to Arg at a position corresponding to position 49 of the amino acid sequence of SEQ ID NO:3; (g 7 ) a substitution of Asn to Gln at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3, a substitution of Thr to Leu at a position corresponding to position 23, and a substitution of Lys to Arg at a position corresponding to position 49; (g 8 ) a substitution of Asn to Gln at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3, a substitution of Thr to Ser at a position corresponding to position 23, and a substitution of Lys to Arg at a position corresponding to position 49; and, a mutant polypeptide chain that contains Val at the position corresponding to position 1 and Ala at the position corresponding to position 29 of the amino acid sequence of SEQ ID NO: 3 and has improved alkali resistance compared to the parent polypeptide chain (however, the mutant polypeptide chain is not a polypeptide chain consisting of any of the amino acid sequences of SEQ ID NOs: 11, 23 to 35); Immunoglobulin-binding protein.
2. The immunoglobulin binding protein of claim 1 , wherein the amino acid sequence of the mutant polypeptide chain has at least 95% identity with the amino acid sequence of SEQ ID NO:
3.
3. 2. The immunoglobulin binding protein of claim 1 , wherein the parent polypeptide chain comprises Val at a position corresponding to position 1 of the amino acid sequence of SEQ ID NO:3 and / or Ala at a position corresponding to position 29 of the amino acid sequence of SEQ ID NO:
3.
4. The immunoglobulin binding protein of claim 1 , comprising two or more of said mutant polypeptide chains.
5. A polynucleotide encoding the immunoglobulin-binding protein according to any one of claims 1 to 4.
6. A vector comprising the polynucleotide of claim 5.
7. A transformant comprising the vector according to claim 6.
8. An affinity carrier comprising a solid phase carrier and the immunoglobulin-binding protein according to any one of claims 1 to 4 bound to the solid phase carrier.
9. A chromatography column comprising the affinity support of claim 8.
10. A method for isolating an antibody or a fragment thereof, which uses the affinity carrier according to claim 8.
11. A method for isolating an antibody or a fragment thereof, using the chromatography column according to claim 9.
12. A method for producing an immunoglobulin-binding protein, comprising expressing the immunoglobulin-binding protein according to any one of claims 1 to 4 in the transformant according to claim 7 or in a cell-free protein synthesis system, or chemically synthesizing the immunoglobulin-binding protein.
13. 1. A method for producing a mutant polypeptide chain, comprising the steps of: A parent polypeptide chain consisting of the amino acid sequence of SEQ ID NO: 3 or an amino acid sequence having at least 90% identity thereto and having immunoglobulin-binding activity is subjected to the following steps: 23 ) to (a 28 ) and (g 1 ) to (g 8 ), comprising introducing any mutation selected from the group consisting of: (a 23 ) substitutions of Asn to Gln at positions corresponding to positions 3, 6, and 11 of the amino acid sequence of SEQ ID NO:3; (a 24 ) a substitution of Asn to Ala at the position corresponding to position 3 of the amino acid sequence of SEQ ID NO:3, and a substitution of Asn to Gln at the position corresponding to position 11; (a 25 ) a substitution of Asn to Asp at a position corresponding to position 3 of the amino acid sequence of SEQ ID NO:3, and a substitution of Asn to Gln at a position corresponding to position 11; (a 26 ) a substitution of Asn to Asp at the position corresponding to position 6 of the amino acid sequence of SEQ ID NO:3, and a substitution of Asn to Gln at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (a 27 ) a substitution of Asn to Asp at a position corresponding to position 3 of the amino acid sequence of SEQ ID NO:3, a substitution of Asn to Asp at a position corresponding to position 6, and a substitution of Asn to Gln at a position corresponding to position 11; (a 28 ) a substitution of Asn to Ala at the position corresponding to position 3, a substitution of Asn to Asp at the position corresponding to position 6, and a substitution of Asn to Gln at the position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3; (g 1 ) a substitution of Asn to Gln at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3, and a substitution of Thr to Arg at a position corresponding to position 23 of the amino acid sequence of SEQ ID NO:3; (g 2 ) a substitution of Asn to Gln at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3, and a substitution of Thr to Leu at a position corresponding to position 23 of the amino acid sequence of SEQ ID NO:3; (g 3 ) a substitution of Asn to Gln at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3, and a substitution of Thr to Ser at a position corresponding to position 23 of the amino acid sequence of SEQ ID NO:3; (g 4 ) a substitution of Asn to Gln at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3, and a substitution of Lys to Arg at a position corresponding to position 49 of the amino acid sequence of SEQ ID NO:3; (g 5 ) a substitution of Asn to Gln at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3, and a substitution of Lys to Arg at a position corresponding to position 58 of the amino acid sequence of SEQ ID NO:3; (g 6 ) a substitution of Asn to Gln at a position corresponding to position 11, a substitution of Thr to Arg at a position corresponding to position 23, and a substitution of Lys to Arg at a position corresponding to position 49 of the amino acid sequence of SEQ ID NO:3; (g 7 ) a substitution of Asn to Gln at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3, a substitution of Thr to Leu at a position corresponding to position 23, and a substitution of Lys to Arg at a position corresponding to position 49; (g 8 ) a substitution of Asn to Gln at a position corresponding to position 11 of the amino acid sequence of SEQ ID NO:3, a substitution of Thr to Ser at a position corresponding to position 23, and a substitution of Lys to Arg at a position corresponding to position 49; the mutant polypeptide chain comprises Val at position 1 and Ala at position 29 of the amino acid sequence of SEQ ID NO:3, and has improved alkali resistance compared to the parent polypeptide chain; method.
14. The method of claim 13, wherein the amino acid sequence of the mutant polypeptide chain has at least 95% identity to the amino acid sequence of SEQ ID NO:
3.
15. The method of claim 13 , wherein the parent polypeptide chain comprises a Val at a position corresponding to position 1 of the amino acid sequence of SEQ ID NO:3 and / or an Ala at a position corresponding to position 29 of the amino acid sequence of SEQ ID NO:
3.
16. A method for producing an affinity carrier, which comprises immobilizing the immunoglobulin-binding protein according to any one of claims 1 to 4 on a solid phase carrier.
Citation Information
Patent Citations
Mutant immunoglobulin binding protein
JP2005538693A
Affinity ligand for immunoglobulin
JP2007252368A
Protein mutation type protein having improved dissociation property in weakly acidic region and antibody scavenger
JP2010081866A
Corrosion-stable chromatography ligand
JP2010156687A
Affinity Chromatography Matrix
JP2012515160A
